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Abstract  
 
Colorectal cancer (CRC) is one of the most common cancers among men and women and 
accounts for 10% of all new cancer cases and cancer deaths each year. Galectin-4 is expressed 
in gastrointestinal tissues but not in kidney, brain, skeletal muscles, heart, liver or lung tissues. 
The main aim of the present study was to define candidate gene(s) for colorectal cancer 
prognosis and to study its regulation.  Using galectin-4 promoter, another aim for this study 
was establishing protein microarray conditions to investigate DNA-protein interaction.  
 
In the present study, I profiled the expression pattern of different stages of six colorectal cancer 
and adenoma cell lines (SW1116, SW480, SW620, Co115, KM20L2, and LT97 in comparison 
to normal colon cell line CCD-18co). In our expression profiling data, we have found that 
galectin-4 was among the genes that are significantly upregulated in LT97 and KM20L2. We 
investigated galectin-4 upregulation as a signature of bad prognosis in colorectal cancer cell 
lines. In addition, we identified one possible mechanism of galectin-4 upregulation which is 
associated with a twin SNPs in the upstream sequence and the first intron. From the sequencing 
results of 115 patients, 26 out of the 115 (22.6%) were found to have the two SNPs together 
(ss217320370 and rs73933062), while the other patients did not carry any of these two SNPs. 
Therefore, we firstly showed that ss217320370 C>A at position 11572034 (a novel SNP was 
identified in the present study) and G>A at position 11571652 (rs73933062) are always 
together in the same individual (twin SNPs). Since the twin SNPs could potentially be 
associated with galectin-4 upregulation via deletion and insertion of new transcription factor 
binding sites, the twin SNPs may have medical impact in colorectal cancer patient.  
 
In parallel, another project was carried out to establish transcription factor protein array for 
DNA-protein interaction detection. For this purpose, fifty transcription factors (TF) proteins 
were expressed and purified. Then, epoxy surface was optimised to immobilize TF proteins at 
37ºC overnight. The DNA-protein interaction was optimised on-chip using retrieved short 
polynucleotide sequences from TransFac database and PCR product of galectin-4 promoter.  
Using galectin-4 promoter and its SNPs, a suitable condition for DNA-protein was established 
on microarray surface. Interestingly, the results of pull down- mass spectrometry were 
compatible with the TF-array results. 
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In conclusion, upregulation of galectin-4 was found to be associated with bad prognosis of 
colorectal cancer. In addition, two SNPs (ss217320370 and rs73933062) were found to be 
associated with galectin-4 upregulation, which might be referred to the changing in the binding 
sequence of the regulatory elements. Using galectin-4 promoter with the twin SNPs was useful 
in setting up TFs-array to detect DNA-protein interactions, since the microarray result was 
concordant with pull down-mass spectrometry analysis of galectin-4 promoter. 
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Zusammenfassung 
 
Kolorektales Karzinom (CRC) gehört zu einer der meist häufigsten Krebsart bei Männern und 
Frauen und zählt jedes Jahr zu 10% aller neuen Krebsfälle und Krebs-bedingten Todesfällen. 
Galectin-4 wird in gastrointestinalen Geweben exprimiert und nicht in Niere, Hirn, 
Skelettmuskulatur, Herz, Leber oder Lunge.  
Ziel dieser Arbeit war es, Kandidatengene für die Prognose von kolorektalem Krebs zu finden 
und deren Regulation zu untersuchen. Ein weiteres Ziel war die Etablierung eines Protein-
Microarrays, um die DNA-Protein-Interaktion unter Verwendung des Gal-4 Promoters zu 
erforschen. 
 
In der vorliegenden Studie habe ich das Expressionsmuster von sechs verschiedenen Stadien 
von kolorektalem Karzinom und Adenoma Zelllinien (SW1116, SW480, SW620, Co115, 
KM20L2 und LT97) im Vergleich zur normalen kolorektalen Zellinie CCD-18co profiliert. In 
den Expressionsprofilierungsdaten fanden wir Galectin-4 unter denjenigen Genen, die 
signifikant in LT97 und KM20L2 hoch reguliert waren. Wir stellten die Hochregulation von 
Galectin-4 in kolorektalen Krebszelllinien als ein Zeichen für schlechte Prognose fest. 
Außerdem identifizierten wir einen möglichen Mechanismus der Hochregulation von Galectin-
4 mit einem assoziierten „Zwillings-SNP“ in der upstream Sequenz und dem ersten Intron. Von 
115 Patienten-Sequenzierergebnissen wurden in 26 Patienten (22,6%) die zwei SNPs 
(ss217320370 und rs73933062) gefunden. Wir haben zunächst gezeigt, dass ss217320370 C>A 
an der Position 11572034 (ein neues SNP wurde in der vorliegenden Studie identifiziert) und 
G>A an der Position 11571652 (rs73933062) immer im gleichen Individuum vorkommen 
(„Zwillings-SNP“). Da diese Zwillings-SNPs mit der Hochregulation von Galectin-4 via 
Deletion und Insertion von neuen Transkriptionsfaktoren Bindestellen assoziiert sind, könnten 
die Zwillings-SNPs eine mögliche medizinischen Auswirkung bei Patienten mit kolorektalem 
Krebs haben.  
 
Parallel wurde ein weiteres Projekt durchgeführt, um einen Transkriptionsfaktor-Array für die 
Detektion von DNA-Protein Interaktion zu etablieren. Zu diesem Zweck  wurden 50 
Transkriptionsfaktoren (TF)-Proteine exprimiert und aufgereinigt. Daraufhin wurde eine 
Epoxy-Oberfläche optimiert, um die TF-Proteine bei 37°C übernacht zu immobilisieren. Die 
DNA-Protein Interaktion wurde auf dem Array optimiert unter Verwendung von kurzen 
Polynukleotid Sequenzen aus der TransFac Datenbank und PCR-Produkten des Galectin-4 
  VI 
Promoters. Unter Verwendung des Galectin-4 Promoters und deren SNPs wurden geeignete 
Bedingungen für DNA und Proteine auf der Microarray Oberfläche etabliert. 
Interessanterweise waren die Ergebnisse der Pull-down-Massen Spektrometrie Ergebnisse 
kompatibel mit denen der Transkriptionsfaktoren-Arrays.  
 
Schließlich wurde eine Hochregulation von Gal-4 assoziiert mit einer schlechten Prognose von 
kolorektalem Krebs gefunden. Außerdem wurde heraus gefunden, dass zwei SNPs 
(ss217320370 und rs73933062) mit der Gal-4 Hochregulation assoziiert sind, was der 
Veränderung in der Bindesequenz des regulatorischen Elements zugeschrieben werden könnte. 
Die Verwendung des Galectin-4 Promoters mit den Zwillings-SNPs war nützlich, um einen 
Transkriptionfaktor-Array für die Detektion von DNA-Protein Interaktionen einzurichten, da 
die Microarray-Ergebnisse einstimmig mit den Pull-down Massenspektrometrie Analysen des 
Galectin-4 Promoters waren. 
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Part I: Expression Profiling Analysis of Colorectal Cancer Cell Lines: 
Reveals a Twin SNPs in Galectin-4 Promoter Associated with its 
Upregulation 
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Introduction 
 
Colorectal cancer (CRC) is the third common cancer in North America in both males 
and females and accounts for 10% of all new cancer cases and cancer deaths each year [1,2]. 
Improvement of the overall 5-year survival rate from colon cancer is due to the early detection 
from increased screening. CRCs arise mostly from adenomatous precursors, and accumulation 
of mutations in proto-oncogenes and tumor suppressor genes (TSGs) leads to progression of 
adenomatous lesions to carcinoma [3,4,5]. High-throughput expression and genotyping arrays 
are starting to generate novel markers and gene signatures that may be of use in the 
management of colorectal cancer. At present, these are not sufficiently validated to be clinically 
useful [6]. 
 
Galectins are family of animal lectins [7]. They are characterized by their ability to 
recognizes β-galactose and their consensus amino acids sequences [8]. All galectins contain 
highly conserved carbohydrate-recognition domains (CRDs) of 130 amino acids responsible for 
carbohydrate binding [9,10]. In gastrointestinal tract, RNAse protection assays showed that 
galectin-4 is expressed in gastrointestinal tissues but not in kidney, brain, skeletal muscles, 
heart, liver or lung tissues. Upon expression of galectin-4, epithelial cells acquired a phenotype 
characterized by the ability to survive lack of nutrients and growth factors for the prolonged 
period of time. Thus, this cellular phenotype is likely to be advantageous in hyperplastic tissues 
of premalignant and malignant tumors [11]. Galectin-4 has been reported to be downregulated 
in colon cancers, suggesting an implication in early colorectal cancer carcinogenesis [12].  
 
In the present study, dependent on our expression profiling results, we have proceeded 
to focus on galectin-4. We have shown galectin-4 upregulation in two cell lines with adenoma 
and Duke’s D colon cancer which was a matter of interest. Therefore, the microarray results 
were validated and the upstream genotyping was studied. We have found two SNPs, one in the 
promoter region and the potential regulatory sequence after the transcription start site. 
Moreover, the two SNPs are always together (a twin SNP). Interestingly, the presence of the 
twin SNPs was associated with galectin-4 upregulation in the cell lines which we also 
confirmed it by the promoter reporter assay. 
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1.1. Colorectal cancer (CRC) 
Colorectal cancer is a major public health problem in the developed countries, since there 
are nearly one million new cases diagnosed worldwide each year and half a million deaths. 
Recent reports show that CRC is the third most frequent cancer in the Western world. In the USA 
it is the most frequent form of cancer among people aged 75 years and older [13,14,15].  
 
1.1.1. Molecular carcinogenesis 
Although there are many alternative pathways to develop colorectal cancer [16], the 
classic model of colorectal cancer is the multistep adenoma-carcinoma  pathway that is 
determined by gatekeeper and caretaker molecular pathways [17]. In the adenoma-carcinoma 
model, colorectal carcinoma arises through a series of well-characterized histopathological 
changes as a result of specific genetic hits in oncogenes and tumor suppressor genes. The analysis 
of the genetic alteration in parallel to the histopathological changes lead to the development of 
the model (figure 1) for the clonal evolution of colorectal tumor by acquisition of sequential 
mutations [4].  
 
 
Figure 1. Adenoma-carcinoma multistep model. The transition from normal colon epithelium 
to premalignant adenoma and then invasive adenocarcinoma is associated in parallel with 
genetic alterations in several genes [18]. 
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About 85% of sporadic colorectal cancer cases have chromosomal instability (CIN), an 
allelic imbalance at several chromosomal loci (including 5q, 8p, 17p, and 18q), chromosomal 
amplification, and chromosomal translocation, which together contribute to tumor aneuploidy 
[17,19,20,21]. On the other hand, the rest of cases 15% are showing microsatellite instability 
(MSI) [22,23], which is indicating the instability of DNA mismatch repair (MMR) system. MSI 
is controlled by several genes (e.g. MLH1, MSH2, and MSH6) and characterized by the 
accumulation of single nucleotide mutation and length alterations in the microsatellite sequence 
[24]. Tumors with MSI are characterized by proximal location, mucinous histology, poor 
differentiation, and lymphocytic infiltration. The molecular mechanism underlying the MSI 
phenotype is loss of mismatch repair genes function through mutation or epigenetic silencing 
[25,26]. CpG island methylator phenotype (CIMP) overlap with MSI and seems to have 
association with MSI in patients who don’t have germline mutation in the MMR genes, which are 
characteristic of hereditary non-polyposis colon cancer HNPCC (Lynch syndrome) [27].  
 
1.1.2. Risk factors 
The most colorectal cancers arise are sporadic. Several risk factors are increasing the 
predisposition to colorectal cancer. Among these factors are increasing the age, gender (higher 
risk in males), previous colonic polyps, and environmental factors (e.g. red meat, high fat, 
diabetes mellitus, obesity, low fibers intake, smoking, and high alcohol consumption) [28]. 
Moreover, inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) represent 
roughly two-thirds of colorectal cancer incidence [29,30], and the risk is proportional to the 
duration of illness [30] and severity of inflammation [31]. In the hereditary syndrome, the 
HNPCC occurs in one in 300 CRC patients and one familial adenomatous polyposis (FAP) arises 
in 7000 of CRC cases [32]. 
 
1.1.3. Colorectal cancer screening 
When screening is recommended, it generally starts with fecal occult blood testing 
(FOBT). Many colorectal cancers bleed into intestinal lumen, and fecal occult blood tests can 
detect the presence of blood that is otherwise unapparent through simple inspection. As blood 
passes through the gastrointestinal tract, it becomes degraded, and depending upon the site at 
which the hemorrhage occurs, blood products in the stool will vary. For example, if a lesion is 
located in the proximal colon, hemoglobin will be completely digested and will be metabolized 
by bacteria into porphyrins. However, if the lesion is in the distal colon, hemoglobin and heme 
will remain mostly intact and unchanged. The design of the FOBT, therefore, must take these 
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variations into consideration. There are several different FOBTs currently available in the 
market. The most commonly used is the Hemocult ІІ test [33]. Stool is placed on guaiac 
impregnated test pads that detect the peroxidase-like activity of heme by changing the color of 
the pad from white to blue. At least three samples must be collected since most colorectal 
lesions have an intermittent bleeding pattern. Red meat and certain fresh fruits and vegetables 
can lead to false positive results. These food sources, therefore, should be avoided for three to 
five days prior to and during testing. Additionally, vitamin C intake should be avoided over the 
same time period because it can inhibit the guaiac reaction leading to false negative results. 
Nonsteroidal anti-inflammatory drugs, alcohol, or any other gastric irritants should also be 
avoided for a three-day period prior to collection, as they may increase gastrointestinal bleeding 
[34]. 
 
Since more than 60% of early lesions were believed to arise in the rectosegmoid areas 
of the large intestine, rigid Sigmoidoscopy was routinely used for screening in the past. Over 
the past several decades, however, there has been an increase in the number of lesions arising 
from more proximal regions of the colon, necessitating the use of flexible, fiberoptic 
sigmoidosopes. Although these methods are very effective and offer a means of removing 
neoplastic polyps, they still leave all lesions beyond the reach of the scope (estimated between 
25% and 34%) undetected. Colonoscopy, based upon the same principle as sigmoidoscopy, 
allows visualization of the entire colon. Although, it is the gold standard in colorectal cancer 
screening, it is very expensive, requires cathartic preparation, and has an increased risk of 
morbidity and mortality [35]. 
The feasibility of fecal DNA screening as an approach to colorectal cancer detection 
was first shown in 1992 with successful assay of mutant k-ras in stool [36]. Stool-based DNA 
testing is a promising new diagnostic tool with potential to improve the overall effectiveness of 
colorectal cancer screening. Early clinical studies suggest that multi-target, DNA-based stool 
test is capable of detecting both premalignant adenomas and cancers with high sensitivity and 
specificity. Screening compliance could be enhanced by the user-friendly features of stool-
based DNA testing which include: the testing is noninvasive, requires no cathartic bowel 
preparation or diet or medication restrictions, and requires just a single specimen per screen 
[37]. 
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1.1.4. Colorectal Cancer staging 
Currently, the recommended staging system is TNM classification, but also Duke’s 
classification is being used. 
 
1.1.4.1. Duke’s classification 
Duke’s system was originally described to be used in rectal carcinoma, but it is also 
applicable in colon cancer. It classifies cancer in the following stages: 1) Duke’s A, in which 
tumor is confined to the intestinal wall, 2) Duke’s B; tumor invading the intestinal wall (serosa 
and/or subserosa), 3) stage C is characterized by lymph node infiltration, and 4) the tumor cells 
are migrating and forming secondary tumor (metastasis) in Duke’s D [38]. 
 
1.1.4.2. TNM staging 
TNM (tumor/ node/ metastasis) is the most common system that used to classify 
colorectal cancer. T is indicating the degree of tumor invasion to the intestinal wall. Lymph 
node involvement is denoted by N. While M represents the metastasis status. According to the 
degree of the involvement, it is again subgrouped as the following: 
 
• Tis: tumor is restricted to the intestinal wall (tumor in situ). 
• T1: tumor invades the submucosa, but is not penetrating muscularis propria. 
• T2: tumor is invading muscularis propria. 
• T3: tumor invades subserosa, but not into peritoneal cavity or other organs. 
• T4: tumor invades other organ(s) or perforates the perineal cavity. 
• Nx: nodal invasion can not be assessed.  
• N0: there is no nodal metastasis. 
• N1: 1-3 pericolic/perirectal nodes involved. 
• N2: 4 or more pericolic/perirectal nodes involved. 
• Mx: Distant metastasis can not be assessed. 
• M0: No distant metastases. 
• M1: Distant metastases. 
  
1.1.5. Prognosis 
The clinicopathological staging is still the gold standard methods for prognosis. 
Histopathological examination of the tumor materials could define the tumor status. Mostly, 
TNM classification is used, but also Duke’s staging system is applied using lymphovascular 
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invasion and tumor grade [38,39]. Some other factors could also influence the clinical outcome 
like obstruction and perforation and pre-operative carcinoembryonic antigen levels [40,41].  
  
Several proteins and genetic markers have been described. The prognostic markers are 
associated with survival that is apart from the treatment effect. Predictive markers are treatment 
indicators that could help to avoid toxicities associated with systemic therapy in patients who 
will not benefit from this treatment [42]. KRAS mutations as a predictive marker in EGFR-
targeted treatment are the most important marker for metastatic colorectal cancer. Mutations in 
exon 2 (codons 12 and 13) and exon 3 (codon 61) of KRAS are associated with the onset of the 
adenocarcinoma pathway in approximately one-third of CRC patients [43]. Mutations in one of 
the three codons compromise the ability of GTPase-activating proteins to affect the inactivating 
hydrolysis of Ras-bound GTP to GDP [44]. Consequently, 99% of patients with mutated KRAS 
do not respond to EGFR inhibition [45].   
 
1.2. Galectins  
Galectins are a family of animal lectins. They are characterized by their ability to 
recognize β-galactose and by their consensus sequences [8].  Galectins show a high level of 
evolutionary conservation. Members of this family are present in organisms from nematodes to 
mammals [46]. All galectins have conserved carbohydrate recognition domain (CRD) of about 
130 amino acids, which is responsible for carbohydrate binding. Fifteen different galectins in 
mammals have been identified and classified according to the CRD to 1) prototype galectins 
(galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15) with one CRD, 2) tandem-repeat type 
galectins (galectin-4, -6, -8, -9, and -12) that consist of two CRDs in single polypeptide chain, 
and 3) chimera type like galectin-3 that contains one CRD and tandem repeats of short amino 
acids stretches fused to the CRD [9,10].  
 
Galectins are involved in several cellular functions. They play different roles in cell-cell 
and cell-matrix adhesion [47]. Some galectins are secreted from the cell through non-classical 
pathway, since galectins a signal sequence that is required for the classical secretion pathway 
[48,49].  Also, galectins could be found as intracellular proteins in different subcellular 
locations [50]. Moreover, galectins play a rule in regulating cell survival and signaling, 
chemotaxis, and cytokines secretion and consequently acting as a regulator of immune cell 
homeostasis and inflammation [51,52].  
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Some galectins are distributed in a wide variety of tissues, whereas others are more 
tissue specific.  The biological rules of galectins are dependent on cellular localization, and cell 
type involved as well [53,54]. Galectins display specific expression pattern in normal as well as 
in pathological situations. Therefore, they could act as interesting biomarkers for diagnosis and 
prognosis as well as targeted therapies [53].  
1.2.1. Galectins expression in normal alimentary canal 
 Nine galectin subtypes have been identified in the mammalian digestive tract (galectin-
1, -2, -3, -4, -6, -7, -8, -9, and -15). Among those, galectin-2, -6, -7, -9, and -15 were detected 
only in the non-human species. In humans, galectin-1 and -8 are located in both nucleus and 
cytoplasm of colonic epithelial calls and stromal cells [55,56,57]. Galectin-4 is only expressed 
in the epithelium of gastrointestinal tract from tongue to colon in the adult and also during the 
development [11,58].   
 
1.2.2. Galectins in colorectal cancer 
Several galectins are involved in the pathogenesis of colorectal cancer, since they are 
contributed in several cellular processes. Therefore, according the rule of galectin(s) in 
tumorigenesis process, they could act as cancer prognostic and predictive markers.  
 
Galectin-1 overexpression is associated with dysplastic transformation [55,56] and 
tumor progression [55,56,59]. This overexpression is mainly detected in stromal cells [60]. 
Previously, galectin-1 overexpression is shown to have a prognostic value [59]. Moreover, a 
previous gene expression profile study found that the responders to pre-operative radiotherapy 
show high level of galectin-1 comparable to the non-responder rectal cancer patients. 
Therefore, it could be used as a therapeutic indicator [60]. 
 
Increased galectin-3 expression in colorectal cancer is associated with neoplastic 
progression [56,59,61,62,63,64,65]. Additionally, marked changes in the subcellular location of 
galectin-3 occur during tumor progression, with loss of nuclear galectin-3 in colon cancer cells 
[66]. At the beginning of tumor progression, nuclear galectin-3 is downregulated. On the other 
hand, in the late stage, the cytoplasmic expression increases [55]. Several studies considered 
that galectin-3 upregulation is associated with poor prognosis [55,59,62,63,64]. Interestingly, it 
has been found that galectin-3 upregulates MUC2 transcription through AP-1 activation [67]. 
MUC2 is strongly expressed in mucinous carcinomas [68]; with consideration that mucinous 
colorectal cancer represents advanced disease stage [69]. Elevated level of serum galectin-3 
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comparable to healthy controls is proportional to tumor progression with the maximum level of 
galectin-3 concentration in the metastatic patients. Thus, galectin levels in the serum samples 
could be interesting as a clinical tool [70].  
 
Galectin-4 upregulation is also associated with poor prognosis. The combination of 
galectin-4 and galectin-1 expression was shown to provide more useful indication for colorectal 
cancer prognosis than galectin-3 [59]. It has been shown previously that T84 human colon 
adenocarcinoma cells exhibiting galectin-3 and galectin-4 localization in lamellipodia domains, 
which could indicate their function in cell-substrate interaction [71].   
 
1.2.3. Galectin-4 
Galectin-4 and an independently discovered 32 kD galectin from C. elegans were the 
first defined galectins with two CRD in the same polypeptide chain [72]. Rat and human 
galectin-4 consist of CRDs of 133aa and 130aa respectively, connected by a link peptide of 
34aa and preceded by 17aa [71,73]. Galectin-4 has two distinctive properties: it tends to be 
associated with the insoluble cellular components, and the link peptide is sensitive to 
proteolysis [74]. In a previous study, RNA protection assay showed that galectin-4 is expressed 
in gastrointestinal tissues, but not in brain, kidney, skeletal muscles, heart, liver or lung tissues 
[11]. Through the nonclassical secretory pathway, galectin-4 can be secreted from basolateral 
and apical sides of the intestinal epithelial cells [58,75].  
  
From the function point of view, the localization and relative insolubility of galectin-4 
in normal epithelia indicate roles in stabilization of cellular junctions and membranes. As the 
other galectins, galectin-4 mediates cell adhesion [71]. In a previous study, wild type and mock 
transfected MDCK cells were unable to grow further and after 7-10 days, they underwent 
apoptosis. On the other hand, MDCK cells that were transfected with the full-length cDNA of 
galectin-4 and expressing this protein were able to survive. Accordingly, the expression of 
galectin-4 could offer the epithelial cells a chance to survive under lack of nutrients and growth 
factors for prolonged period of time. Therefore, such a cellular phenotype is likely to be 
advantageous in hyperplastic tissues of premalignant and malignant tumors [11].  
 
Previous studies referred the expression of high galectin in the intestinal mucosa to the 
rule of galectin in the immune system, since it serves as a pathogen recognition protein [76,77]. 
Previous studies suggest that several galectins may recognize blood group antigens [78]. 
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Recently, it has been reported that galectin-4 and galectin-8 recognize and kill human blood 
group antigen-expressing E. coli while failed to alter the viability of other E. coli strains or 
other Gram-negative or Gram-positive organisms both in vivo and in vitro [79].  
 
The aim of this part of the thesis was according to the experiment as the following: 
1. The expression profiling of colorectal cancer cell lines was to find the proper gene 
candidate(s) according to the stage which could have diagnostic and prognostic value. 
2. Galectin-4 promoter study was to understand the gene regulation and the impact of 
SNPs on promoter activity. Meanwhile, the twin SNPs and their effect on the binding 
activity of galectin-4’s promoter was valuable in TFs-array application. 
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Material and Methods 
 
2.1. Materials 
 
2.1.1. Chemicals 
Name  Manufacturer  
2′-Deoxyadenosine 5′-Triphosphate  MBI Fermentas, St. Leon-Rot  
2′-Deoxycytidine 5′-Triphosphate  MBI Fermentas, St. Leon-Rot  
2′-Deoxyguanosine 5′-Triphosphate  MBI Fermentas, St. Leon-Rot  
2′-Deoxythymidine 5′-Triphosphate  MBI Fermentas, St. Leon-Rot  
Agar Roth, Karlsruhe, Germany 
Agarose Invitrogen, Carlsbad, USA 
Ammoniumpersulfate (APS) Roth, Karlsruhe, Germany 
Ampicillin (sodium salt) Genaxxon, Munich, Germany 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Deisenhofen  
EDTA Sigma-Aldrich, St.Louis, USA 
Ethanol, absolute Riedel de Haën Sigma, Seelze, Germany 
Ethidium bromide AppliChem, Darmstadt, Germany 
First strand-buffer  Invitrogen, Karlsruhe, Germany 
FluoroLink™ Cy3-dCTP. Cy5-dCTP  Amersham-Pharmacia-Biotech, Freiburg, 
Germany 
Glycerol J.T.Baker, Deventer, Holland 
PCR- buffer, 10x  Qiagen, Hilden, Germany 
Penicillin/Streptomycin  Invitrogen, Karlsruhe, Germany 
Random Hexamer Primer (pd(N)6)  Amersham-Pharmacia-Biotech, Freiburg, 
Germany 
SlideHyb™-Hybridization buffer 1  Ambion, Huntingdon, Cambridgeshire, UK  
Sodium chloride Riedel de Haën Sigma, Seelze, Germany 
TEMED Roth, Karlsruhe, Germany 
Tetracyclin Genaxxon, München, Germany 
Tris-base Sigma-Aldrich, St.Louis, USA 
Tris-HCl Sigma-Aldrich, St.Louis, USA 
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Triton X 100 Gerbu, Gaiberg, Germany 
Triton- X 100  Sigma-Aldrich, Deisenhofen  
Trypsin/ EDTA  Invitrogen, Karlsruhe , Germany 
Tryptone/Peptone Roth, Karlsruhe, Germany 
Tween 20 Sigma-Aldrich, St.Louis, USA 
Yeast extract Gerbu, Gaiberg, Germany 
β-Mercaptoethanol   Sigma-Aldrich, Deisenhofen  
 
 
2.1.2. Enzymes 
Name  Manufacturer  
HindIII NEB, Frankfurt, Germany 
NheI NEB, Frankfurt, Germany 
RNAse A, lyophilized  Sigma-Aldrich, Deisenhofen  
RNAse H (2 U/μl)  Invitrogen, Karlsruhe, Germany 
RNAse Out–Inhibitor (40 U/μl)  Invitrogen, Karlsruhe, Germany 
Superscript ™ III RT (200 U/μl)  Invitrogen, Karlsruhe, Germany 
XhoI NEB, Frankfurt, Germany 
 
  
2.1.3. Kits 
Name Manufacturer 
Allprep DNA/RNA/Protein minikit Qiagen, Hilden, Germany 
Dual-luciferase reporter assay system Promega, Madison, WI 
ECL Western Blotting Detection System Amersham Pharmacia Biotech, 
Buckinghamshire, UK 
Effectene transfection reagent Qiagen, Hilden, Germany 
Pierce Pull-Down Biotinylated Protein:Protein 
Interaction kit 
Thermo Scientific, Rockford, USA 
QIAquick PCR-Purification Kit  Qiagen, Hilden, Germany 
Qproteome Mammalian Protein Kit  Qiagen, Hilden, Germany 
QuantiFast SYBR Green RT-PCR Kit Qiagen, Hilden, Germany 
QuantiFast SYBR Green RT-PCR Kit Qiagen, Hilden, Germany 
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2.1.4. Buffers  
Name  Composition  
Binding buffer 5X 0.1M Hepes pH 8.0, 0.25M KCl, 25mM DTT, 
0.25mM EDTA, 5mM MgCl2, 25% v/v 
glycerol 
Ethidium bromide solution for staining  0,5 μg/ml End conzentration 
Laemmli buffer 30,1 g Tris Base, 144,2 g Glycine, 50 ml SDS 
(20%), ad 1 l dH2O 
LB-Agar LB-Medium + 1,5% (w/v) Agar 
LB-Medium (1 liter) 10 g Tryptone/Pepton, 5 g yeast extract, 10 g 
NaCl, pH 7.2 
SSC (20x)  15,36% (w/w) NaCl, 7,73% (w/w) Tri-sodium 
citrate, 76,91% (w/w) d H2O  
TAE buffer (50x)  0.4 M Tris Base, 0.4 M acetic acid, 20 mM 
EDTA (pH 8)  
TBS 10x (1 liter) 50 mM Tris, 150 mM NaCl mit HCl, pH 
7.5 
TBST 1X TBS/ 0,05% Tween20 
Transfer buffer 150 mM Glycine, 25 mM Tris-base, 20% 
Ethanol 
  
 
2.1.5. Consumables 
Name  Manufacturer  
6-well cell culture plate  Griener Bio One, Frickenhausen  
Adhesive foil for microtiter plates  Nalge Nunc Int., Rochester, NY  
Cell culture flask, 250 ml  Griener Bio One, Frickenhausen  
Cell culture flask, 75 ml  Griener Bio One, Frickenhausen  
Cell culture Petri dishes 96x20mm stock 
Cover slip  Erie Scientific Company, Portsmouth, USA  
Falcon 15 ml and 50 ml  Becton Dickinson, Heidelberg 
Lazy-L-Spreaders Sigma-Aldrich, St.Louis, USA 
Nitril gloves Nitril, Microflex, Wien, Austria 
Parafilm PM 996, Pechiney Plastic packaging 
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PCR-plate, 96er  Steinbrenner, Neckargemünd  
Reaction tubes 1,5 ml und 2 ml  Eppendorf, Hamburg  
Sterile filter 500 ml Nalgene, Rochester, USA 
UV cuvette 220-1600 nm  Eppendorf, Hamburg  
Lazy-L-Spreaders Sigma-Aldrich, St.Louis, USA 
 
 
2.1.6. Equipment 
Name  Manufacturer  
Centrifuge  5810R, Eppendorf, Hamburg Germany 
Centrifuge 5415D, Eppendorf, Hamburg Germany 
Hoefer TE 70 (Semi dry Wester-Blot) Amersham Bioscience, Piscataway, USA 
LightCycler 480  Roche Diagnostics, Mannheim  
MicroGrid spotter  BioRobotics, Apogent Discoveries, USA  
Mini-Protean®3 electrophoresis chamber and 
casting unit 
BioRad, Waltham, USA 
ND 1000, NanoDrop, Spectrophotometer NanoDrop, Wilmington, DE USA 
Oven    Haereus, Hanau, Germany 
pH-Meter MP 230, Mettler Toledo, Germany 
Photometer Nanodrop ND-1000   
ScanArray 4000XL Perkin Elmer, Boston, MA, USA 
ScanArray 5000 Perkin Elmer, Boston, MA, USA 
Vacuum-concentrator  H.Saur Laborbedarf, Reutlingen  
 
 
2.1.7. Antibodies and electrophoresis ladders 
Name  Manufacturer  
GeneRuler 1 kb DNA marker  MBI Fermentas, St. Leon-Roth  
GeneRulerTM 100 bp DNA marker  MBI Fermentas, St. Leon-Roth  
Anti human galectin-4 R&D system, Minneapolis, MN, USA 
 
  
2.1.8. Primers 
Primer  Sequence  
qRT-PCR LGALS4 Hs_LGALS4_1_SG QuantiTect Primer Assay, Qiagen, 
Hilden, Germany 
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LGALS4-700F TTCACAGTTGCTGGGAGAGG. 
LGALS4-700R GATGACGAGGGCCAACAGTTAGACGTG 
LGALS4 XhoI F AAAAAAACTCGAGTTCACAGTTGCTGGGAGAGG 
LGALS4 HindIII R GGGGGGAAGCTTGCTGCGCTAGTGGCTGGTC 
LGALS4 var2 NheI F AAAAAAAGCTAGCCCACCATCTCCCACTCCTG 
LGALS4 var2 HindIII R TTTGGGGAAGCTTGATGACGAGGGCCAACAGTTAGA 
LGALS4 2var NheI F AAAAAAAGCTAGCTTCACAGTTGCTGGGAGAGG 
LGALS4 2var HindIII R TTTGGGGAAGCTTGATGACGAGGGCCAACAGTTAGA 
ACO1 F gcaggcaccacagactatcc 
ACO1 R cagcagcatcaaacacatca 
ENO1 F tcccaacatcctggagaataa 
ENO1 R atgccgatgaccaccttatc 
FUBP1 F gggctgcttattacgctcac 
FUBP1 R tggattctgctgatctccttg 
HNRNPK F cagacgccattatcctctgtt 
HNRNPK R cccagtgctgcagtagcc 
FUBP2 F gccgcttactacggacagac 
FUBP2 R acattcattcgattcattgagc 
MYBBP1a F ggcatccacctcctcaagt 
MYBBP1a R agacttttcctgatgcaggtct 
PRDX1 F cactgacaaacatggggaagt 
PRDX1 R tttgctcttttggacatcagg 
PUF60 F ggcgaccatagctctcca 
PUF60 R cctgtggaggtttccatttg 
RBBP7 F acgcaagatggcgagtaaag 
RBBP7 R cggtgtattcttcttccagatttt 
FUS F ggccagagcagctattcttc 
FUS R ggggagttgactgagttcca 
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2.2. Methodology   
 
2.2.1. Cell culture 
Seven cell lines have been used in the present study, a normal colon cell line CCD-
18Co (ATCC) and LT97 as adenoma cell line (as a gift from Brigitte Marian) and SW1116, 
Sw480, Co115, SW620, and KM20L2 from Duke’s stage A, B, C primary tumor, C lymph 
node infiltration, and D respectively (as a gift from Gabriela Aust, Heike Allgayer, Richard 
Iggo, Francis RAUL, Øystein Fodstad). The maintenance of the cells was carried out in the 
proper medium for each cell line at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
 
2.2.2. mRNA Expression Profiling 
 
2.2.2.1. Microarray production 
Amino-modified PCR products of 3872 human cDNAs have been arrayed in duplicate 
on epoxysilane surface (Schohtt Nexterion AG, Jena, Germany) with a MicroGridII arrayer 
(BioRobotics, Cambridge, UK) using SMP3 pins (TeleChem International Inc., Sunnyvale, 
Calif., USA). 
 
2.2.2.2. Sample preparation and hybridization 
DNA, RNA, and protein samples have been isolated from cell pellets with Allprep 
DNA/RNA/Protein minikit (Qiagen, Hilden, Germany). Flourescently labeled cDNAs were 
prepared from 10µg total RNA by incorporation of Cy3- or Cy5- labeled dCTP (Amersham 
Bioscience, Freiburg, Germany) during the first strand synthesis. The hybridization has been 
done in SlideHyb buffer 1 (Ambion Inc., Austin, Tex., USA) under glass cover slips at 62°C in 
water bath overnight.  
 
2.2.2.3. Detection and analysis 
Following the overnight hybridization, the slides have been washed in 0.1X SSC 
(15mM sodium chloride and 1.5mM sodium citrate) for 3 minutes and dried by nitrogen. 
Subsequently, the fluorescence signals have been detected using ScanArray5000 confocal laser 
scanner (Packard, Billerica, Mass., USA).  Each cell line cDNA was hybridised versus the 
normal colon cells cDNA four times. Moreover, the fluorescent labelling has been switched 
every hybridization. Finally, at least eight data points per gene and individual experiment 
condition (duplicate spots on each array, four hybridizations per sample inclusive dye swap) 
were obtained. The signal intensities have been quantified by GenePix Pro 4.1 analysis 
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software (Axon Instruments Inc., Union City, Calif., USA). Data quality assessment, 
normalization and correspondence cluster analysis were performed with the MIAME- 
compatible [80] analysis and data warehouse software M-ChiPS [81]. 
 
Cluster analyses have been performed using correspondence analysis [82], which is an 
explorative computational method for the investigation of associations between variables, such 
as genes and patient samples, in a multidimensional space. It simultaneously displays data for 
two or more variables in a low-dimensional projection, thus revealing associations between 
them. Additionally, the cluster analysis has been repeated using MultiExperiment viewer 
(MeV_4). MeV is a desktop application for the analysis, visualization and data mining of large-
scale genomic data. It is a versatile microarray tool, incorporating sophisticated algorithms for 
clustering, visualization, and classification [83,84].  
 
2.2.3. Galectin-4 validation by qRT-PCR 
Since galectin-4 was significantly upregulated in LT97 (adenoma cell line) and 
KM20L2 (Duke’s D cell line) while not regulated in the other cell lines, galectin-4 was one of 
the interesting differentially regulated genes in the expression profiling. Therefore, we chose 
galectin-4 for further validation by qRT-PCR and subsequently detailed study of promoter 
variations using Hs_LGALS4_1_SG QuantiTect Primer Assay and one-step QuantiFast SYBR 
Green RT-PCR Kit (Qiagen, Hilden, Germany) and the Light Cycler 480 instrument (Roche 
Diagnostics) have been used. We started with 10ng of RNA, following the manufacturer's 
instructions, a reverse transcription step has been done at 50°C for 10 minutes followed by 
PCR initial activation step for 5 minutes at 95°C. Afterward, 40 cycles of 10 seconds 
denatuaration at 95°C, 20 seconds annealing at 55°C, and extension at 68°C for 20 seconds. A 
final melting curve to check fidelity was done from 95°C for 5 seconds, 65°C 1 minute with 5-
10 signal acquisitions every 1°C up to 97°C. Expression levels were normalised relative to the 
transcription level of α-tubulin. All samples were run in triplicate. 
 
2.2.4. Western blotting for galectin-4 
Total protein was extracted using Qproteome mammalian protein preparation kit 
(Qiagen, Hilden, Germany) according to the manufacturer's instructions. Protein samples were 
resolved on SDS-polyacrylamide gel. Then, proteins have been electrophoretically transferred 
to nitrocellulose membranes (Amersham Pharmacia Biotech, Buckinghamshire, UK) followed 
by blocking for 1 h in 3% nonfat milk in TBST. Subsequently, the membrane has been 
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incubated in the primary antibody against galectin-4 (R&D system, Minneapolis, MN, USA) 
for 1 h. After incubation with secondary antibody, bands were detected by chemiluminescence 
using the ECL Western Blotting Detection System (GE Healthcare, Amersham, 
Buckinghamshire, UK). 
 
2.2.5. Galectin-4 promoter analysis 
2.2.5.1. Promoter sequencing 
The promoter sequence has been retrieved using Transcriptional Regulatory Element 
Database [84,85]. We have sequenced the promoter from –400 to +300 using LGALS4-700F: 
TTCACAGTTGCTGGGAGAGG and LGALS4-700R: 
GATGACGAGGGCCAACAGTTAGACGTG. The primers have been designed using Primer3 
(2). The amplified products from the seven cell lines were Sanger sequenced at the GATC 
Biotech, Konstanz, Germany. 
 
2.2.5.2. Luciferase reporter assay  
According to the results from the promoter sequencing, three fragments of the galectin-
4 promoters have been cloned in pGL4.1 (Promega, Madison, WI).  In details, one large 
fragment contains the site of two variations found in our study and each of the other two 
fragments contain one site of variation. Simply, the PCR fragments were amplified from the 
wild and the mutant cell lines using the following primers: LGALS4 XhoI F: 
AAAAAAACTCGAGTTCACAGTTGCTGGGAGAGG and LGALS4 HindIII R: 
GGGGGGAAGCTTGCTGCGCTAGTGGCTGGTC for –233 variation, for the 2nd variation at 
+150: LGALS4 var2 NheI F: AAAAAAAGCTAGCCCACCATCTCCCACTCCTG 
andLGALS4 var2 HindIII R: TTTGGGGAAGCTTGATGACGAGGGCCAACAGTTAGA 
and for the two variation: LGALS4 2var NheI F: 
AAAAAAAGCTAGCTTCACAGTTGCTGGGAGAGG and LGALS4 2var HindIII R: 
TTTGGGGAAGCTTGATGACGAGGGCCAACAGTTAGA.  Following the PCR 
amplification, the products have been digested and ligated into pGL4.1 plasmid. The cell lines 
were cotransfected with constructed plasmid and pRL-TK using effectene kit (Qiagen, Hilden, 
Germany). After 24 hours, the cells were lysed and the cell lysates were analysed for firefly 
luciferase activity with the dual-luciferase reporter assay system (Promega, Madison, WI). 
Firefly activity was normalized to Renilla (pRL-TK). 
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2.2.5.3. Pull down of the binding proteins 
The PCR fragments of galectin-4 promoter (the wild and the variants) were used as 
baits for the DNA binding proteins using Pierce Pull-Down Biotinylated Protein:Protein 
Interaction kit (Thermo Scientific, Rockford, USA). The kit had been modified to suit 
DNA:Protein interactions by changing the binding buffer. The promoter fragments were 
amplified using Biotinylated primers and reacted with immobilized streptavidin column. The 
CO115 nuclear proteins were extracted by NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (Thermo Scientific, Rockford, USA). Then diluted in 5X binding buffer (0.1M Hepes 
pH 8.0, 0.25M KCl, 25mM DTT, 0.25mM EDTA, 5mM MgCl2, 25% v/v glycerol) and 
incubated on the column 30 minutes at room temperature. Afterward, the columns were washed 
with TBST and the binding proteins eluted with Lamelli buffer at 95°C. Subsequently, the 
eluted protein samples were resolved on SDS-polyacrylamide gel. Subsequently, the bands 
were cut for mass spectrometry analysis (core facility, DKFZ, Heidelberg, Germany). 
 
2.2.5.4. Methylation status 
The CpG island was identified and the proper primers for the bisulfite sequencing were 
designed using MethPrimer [86]. Genomic DNA was treated with EpiTect DNA Bisulphite 
Modification Kit (Qiagen, Hilden, Germany). The bisulfite treated DNAs were amplified using 
LGALS4-cpg F: TTTTTATTTTGGGTATAAGAGTTATTAT and LGALS4-cpg R: 
ATAAAACCTAAACTAACATCTCACC and subsequently were Sanger sequenced at the 
GATC Biotech, Konstanz, Germany. 
 
2.2.5.5. Promoter genotyping in colorectal cancer patient samples 
We screened the promoter sequences of galectin-4 for the two SNPs in colorectal 
lesions patients using LGALS4-700F: TTCACAGTTGCTGGGAGAGG and LGALS4-700R: 
GATGACGAGGGCCAACAGTTAGACGTG. 115 samples were collected as the following: 1) 
18 colorectal tumors from the National Center of Tumor Diseases (NCT), Heidelberg, 
Germany, 2) DNA isolated from lesions and their adjacent normal tissues from 54 patients (27 
colorectal cancer patients, 15 ulcerative colitis patients, and 12 patients with adenomatous 
polyps) which are collected from the Egyptian National Cancer Institute (ENCI), Cairo, Egypt. 
3) 15 colorectal tumor samples from the Egyptian National Cancer Institute (ENCI), Cairo, and 
4) 28 DNA samples isolated from blood of gastrointestinal tumors (the Egyptian National 
Cancer Institute (ENCI), Cairo). 
 
Results 
20 
 
3. Results 
 
3.1. Expression profiling classifies colorectal cancer cell lines to bad and 
good prognosis rather than tumor stages 
Six colorectal cancer cell lines that represent different Duke’s stages were profiled for 
gene expression versus a normal colon cell line. Clustering of the samples using 
correspondence and MeV analyses indicate an association between them. As shown in figure 1 
a and b, the colorectal cancer cell lines are classified nicely according to their stage and degree 
of aggressiveness except LT97 (benign adenoma cell line) that is classified with grade D cell 
line (KM20L2). The convergent clustering of LT97 and KM20L2 was the main motivation to 
pursue the present study. Since LT97 is a cell line derived from hereditary polyposis patient, it 
could be an indication for bad prognosis. Accordingly, we have selected galectin-4 gene for 
further analyses because it was significantly upregulated in LT97 and KM20L2 but not the rest 
of the cell lines (figure 2). 
 
 a   
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b 
 
 
Figure 2. The expression profiling results of the six colon cell lines compared to the normal 
colon cell lines. a. the correspondence cluster analysis of transcript profiles. In the resulting 
biplot, each hybridization of a cell line is depicted as a colored square. Genes that exhibited 
significantly differential transcription level are shown as black dots. The closer the 
colocalizaion of two spots (both genes and cell lines), the higher the degree of association 
between them. b. The heatmap shows the hierarchical clustering of six cell lines based on 
expression profiling. In the heatmap, red represents high expression, black represents median 
expression, green represents low expression. 
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3.2. Galectin-4 is significantly upregulated in LT97 and KM20L2 
Among 417 filtered differentially regulated genes from the microarray results, galectin-
4 showed significant upregulation in LT97 and KM20L2 (benign adenoma and Duke’s D cell 
lines), which was interesting to pursue more investigations and to focus on the upregulation 
mechanism of galectin-4. Subsequently, qRT-PCR and Western blotting were used to validate 
the upregulation that has been shown in the microarray data. The results of the qRT-PCR 
showed huge upregulation of galectin-4 in LT97 and Km20l2 which exceed 350 and 700 fold 
change respectively as shown in (figure 3).  Moreover, CO115 showed a slight upregulation in 
the mRNA level, unless it didn’t show protein expression in the Western-blotting.  
 
 
 
 
 
Figure 3. qRT-PCR of galectin-4 for six cell lines (LT97, SW1116, SW480, SW620, Co115, 
and KM20L2) in comparison to normal colon cell line as a control. As shown in figure, LT97 
and KM20L2 exhibit significant upregulation (350, 700 fold change respectively). Also, 
CO115 showed a slight upregulation in the mRNA level (4 fold change). 
  
 
 
3.3. A twin SNPs in the regulatory region are associated with galectin-4 
upregulation in LT97 and KM20L2 
Upon the sequencing results of the LGALS4 upstream sequence (700bp including the 
first exon and part of the first intron), two SNPs were found in LT97 and KM20L2 cell lines, 
one before the transcription start site TSS and the second in the first intron (in a potential 
regulatory region) as shown in figure 4. The first exon SNP is previously known as 
rs73933062, but it is not known for medical impact. The upstream SNP was not recorded 
before and it is at contig position 11572034 C>A or at 39303816 C>A chromosomal position 
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and accordingly. We submitted this SNP and it got submission SNP access number 
ss217320370. In both cell lines, the two SNPs were observed together in the same sequence, 
and that why we called them a twin SNP.  
 
 
 
 
 
Figure 4. LGALS4 is expressed from the minus strand and located on chromosome 19. The 
position of the two SNPs in the upstream sequence and the first intron of galectin-4 is showed 
in this figure comparable to transcription start site (TSS). Also the promoter sequence that was 
retrieved Transcriptional Regulatory Element Database.  
 
 
3.4. Effect of the two SNPs activity on promoter 
The two SNPs are located in the regulatory region of galectin-4: 1) ss217320370 is in 
the promoter sequence before the TSS and 2) rs73933062 is in a putative enhancer region, after 
the TSS but not in the translated sequence. Therefore, the luciferase activity of the promoter 
has been evaluated using pGL4.10 constructs for each SNP and the two SNPs as the following: 
1) pGL4.10-wt1 and pGL4.10-mt1 which contains respectively the A or A at position 
11572034, 2) pGL4.10-wt2 and pGL4.10-mt2 represents rs73933062 with G or A, and 3) two 
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constructs include the SNPs named as pGL4.10-2wt and pGL4.10-2mt. Co115 cell line was 
transfected with each construct (which contains Firefly luciferase as a reporter gene) and pRL-
TK (which has a Renilla luciferase). Then, the Firefly/Renilla ratio was calculated for 
transfection efficiency control and the fold changes were calculated by dividing Firefly/Renilla 
ratio from variant-2 construct over Firefly/Renilla ratio of variant-1 construct. We have got the 
following results for the 3 different constructs: 1) a slight change (1.3 fold change) in the 
construct pGL4-mt1, which contains C/A at 11572034-contig position, 2) interestingly, the 
construct pGL4-mt2 that has rs73933062 showed 1500 folds change over pGL4-wt2, and 3) 
nearly 4 folds change has been obtained in the case of pGL4-2mt relative to pGL4-2wt that 
represent the construct that contains the two SNPs site (figure 5). 
 
 
Figure 5. The transient transfection of luciferase reporter construct in Co115 cell line results: it 
shows the variation of the presence of each SNP individually comparable to the predominant 
genotype and also the combination of the two SNPs in the same construct. The presence of a 
mere ss217320370 in the construct mildly increased the luciferase activity 1.3 fold change in 
comparison to the normal construct. On the other hand, pGL4-mt2 that has rs73933062 showed 
1500 folds change over pGL4-wt2. The combination of the two SNPs in one construct 
increased the luciferase activity four times. 
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To confirm rs73933062 luciferase activity results, SW1116 and SW620 were 
transfected with the construct, which contains the target SNP and the experiment was repeated 
twice independently. Interestingly, 36 and 37-fold change in the luciferase activity were 
obtained respectively for SW620 and SW1116 (figure 6).  
 
 
 
Figure 6. The transfection results of SW1116 and SW620 with the luciferase construct that 
contains rs73933062 SNP. In comparison to the wild type construct, respectively, 37 and 36 
fold change increasing in the luciferase activity in SW1116 and SW620. 
 
 
 
3.5. The two SNPs are affecting the protein binding sites 
In order to understand the mechanism underlying the upregulation effect associated 
with the presence of the two SNPs, a pull down experiment was done to investigate the DNA-
binding proteins that tethered to each variant. Interestingly, we have found that both 
rs73933062 and contig 11572034 C/A are introducing and deleting binding sites. Among the 
response element that have been omitted: Aconitase 1 (ACO1), Retinoblastoma Binding 
Protein-7 (RBBP7), siah binding protein 1 (PUF60), and DAZ associated protein. On the other 
hand, the two SNPs offered response elements for some interacting proteins such as MYB 
binding protein 1a (MYBB1a), fatty acid binding protein 5 (FABP5) and peoxiredoxin 
(PRDX1). Moreover, the pull-down experiment manifested the regulatory proteins that bind to 
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galectin-4 promoter like enolase-1 (ENO1), fuse-binding protein-1 (FUBP1), fuse-binding 
protein-2 (FUBP2 or KSRP), FUS, and LBP1a. 
 
 
2mt (ss217320370 C>A and rs73933062 G>A) 
54 kDa protein 
90kDa heat shock protein  
adenomatosis polyposis coli  
alpha enolase  
alpha-tubulin  
annexin A2 isoform 2  
apolipoprotein D, apoD 
apoptosis inhibitor 5 isoform b  
arginase (EC 3.5.3.1)  
ATP-dependent DNA helicase II  
ATP-dependent DNA helicase II, 70 kDa subunit  
caspase 14 precursor  
cathepsin D preproprotein  
CCT8 protein  
Chain A, High Resolution Solution Nmr Structure Of Mixed Disulfide Intermediate Between 
Mutant Human Thioredoxin And A 13 Residue Peptide Comprising Its Target Site In Human 
Nfkb 
Chain A, Single Stranded Dna-Binding Domain Of Human Replication Protein A Bound To 
Single Stranded Dna, Rpa70 Subunit, Residues 183-420 
chaperonin (HSP60)  
chaperonin containing TCP1, subunit 6A isoform a  
chaperonin containing TCP1, subunit 7 isoform a  
colonic and hepatic tumor over-expressed protein isoform a  
cystic fibrosis antigen 
cytoplasmic chaperonin hTRiC5  
desmoplakin I  
DNA helicase Q1  
DNA topoisomerase I  
DNA topoisomerase II  
DNA-binding protein  
Dsc1a precursor  
elongation factor-1 alpha  
enhancer protein  
enolase  
eukaryotic initiation factor 5A  
eukaryotic translation elongation factor 1 alpha 1  
eukaryotic translation elongation factor 1 gamma  
eukaryotic translation elongation factor 2  
eukaryotic translation initiation factor 4A isoform 1  
fatty acid binding protein 5 (psoriasis-associated)  
filaggrin family member 2  
FUBP1 protein  
FUSE binding protein 2  
gastric cancer-related protein FKSG9  
glyceraldehyde-3-phosphate dehydrogenase  
growth regulated nuclear 68 protein 
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heat shock 70kDa protein 8 isoform 1  
heat shock protein  
heat shock protein 90  
heterogeneous nuclear ribonucleoprotein A/B isoform a  
heterogeneous nuclear ribonucleoprotein L  
histone H4 
hnRNP U protein  
Hsp89-alpha-delta-N  
insulin-like growth factor 2 mRNA binding protein 1 isoform 1  
K channel:SUBUNIT=beta 
LBP-1a 
lysozyme precursor (EC 3.2.1.17)  
M4 protein  
mitochondrial ATP synthase beta subunit precursor  
mutant beta-actin (beta~-actin)  
MYB binding protein (P160) 1a  
myoblast antigen 24.1D5  
nuclear DNA helicase II  
nuclear factor IV  
nuclear respiratory factor 1  
nucleolin  
phosphoglycerate dehydrogenase  
phospholipase C-alpha  
poly(ADP-ribose) polymerase  
poly(rC) binding protein 2 isoform b  
polypyrimidine tract-binding protein 1 isoform a  
prolactin-induced protein precursor  
RecName: Full=Desmoglein-1; AltName: Full=Desmosomal glycoprotein 1; Short=DG1; 
Short=DGI; AltName: Full=Pemphigus foliaceus antigen; Flags: Precursor 
RecName: Full=Probable ATP-dependent RNA helicase DDX17; AltName: Full=DEAD box 
protein 17; AltName: Full=RNA-dependent helicase p72; AltName: Full=DEAD box protein p72 
replication protein A1  
ribophorin I precursor  
Ro ribonucleoprotein  
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 12  
serum albumin  
spliceosomal protein SAP 155  
splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated)  
splicing factor SF3a60  
squamous cell carcinoma antigen  
STE20-like kinase  
structural maintenance of chromosomes 3  
suprabasin isoform 1 precursor  
t-complex polypeptide 1  
testicular H1 histone  
The deletion results in premature stop  
thiol-specific antioxidant protein  
TLS protein 
topoisomerase I  
TR4 orphan receptor  
transcription factor LSF  
transformation upregulated nuclear protein  
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transglutaminase E3  
TUBB protein  
ubiquitin 
UV excision repair protein RAD23 homolog B  
vimentin  
Zn-alpha2-glycoprotein  
 
Table 1. The list of proteins which bound to LGALS4 upstream sequence, which contains the 
twin SNP (A instead of C and G). White box indicates common protein for wild and mutant 
types and orange boxes represent the unique proteins for each genotype. 
 
 
 
2wt (wild type) 
54 kDa protein  
90kDa heat shock protein  
aconitase 1  
adenomatosis polyposis coli  
alpha-tubulin  
annexin A2 isoform 2  
apoptosis inhibitor 5 isoform b  
arginase (EC 3.5.3.1)  
ATP-dependent DNA helicase II  
ATP-dependent DNA helicase II, 70 kDa subunit  
caspase 14 precursor  
cathepsin D preproprotein  
CCT8 protein  
cell cycle protein p38-2G4 homolog  
CGI-46 protein  
Chain A, High Resolution Solution Nmr Structure Of Mixed Disulfide Intermediate Between Mutant 
Human Thioredoxin And A 13 Residue Peptide Comprising Its Target Site In Human Nfkb 
Chain A, Single Stranded Dna-Binding Domain Of Human Replication Protein A Bound To Single 
Stranded Dna, Rpa70 Subunit, Residues 183-420 
chaperonin (HSP60)  
chaperonin containing TCP1, subunit 6A isoform a  
chaperonin containing TCP1, subunit 7 isoform a  
cystic fibrosis antigen 
cytoplasmic chaperonin hTRiC5  
damage-specific DNA binding protein 2  
DAZ associated protein 1  
DEK oncogene isoform 1  
desmoplakin I  
DNA helicase Q1  
DNA topoisomerase I  
DNA-binding protein  
Dsc1a precursor  
enolase 1  
eukaryotic initiation factor 5A  
eukaryotic translation elongation factor 1 gamma  
eukaryotic translation elongation factor 2  
filaggrin family member 2  
FUBP1 protein  
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FUSE binding protein 2  
glyceraldehyde-3-phosphate dehydrogenase  
growth regulated nuclear 68 protein 
GRP78 precursor  
heat shock 70kDa protein 8 isoform 1  
heat shock protein  
heat shock protein 90  
Heat shock protein HSP 90-alpha 2  
heterogeneous nuclear ribonucleoprotein A/B isoform a  
heterogeneous nuclear ribonucleoprotein L  
histone H4 
hnRNP U protein  
insulin-like growth factor 2 mRNA binding protein 1 isoform 1  
K channel:SUBUNIT=beta 
LBP-1a=transcription factor binding to initiation site of HIV-1 {alternatively spliced} (human, Namalwa 
cells, Peptide, 504 aa) 
lysozyme precursor (EC 3.2.1.17)  
M4 protein  
mitochondrial ATP synthase beta subunit precursor  
mutant beta-actin (beta~-actin)  
nuclear factor IV  
nuclear respiratory factor 1  
nucleolin  
p53 cellular tumor antigen  
phosphoglycerate dehydrogenase  
phospholipase C-alpha  
poly(ADP-ribose) polymerase  
poly(rC) binding protein 2 isoform b  
polypyrimidine tract-binding protein 1 isoform a  
prolactin-induced protein precursor  
RecName: Full=Desmoglein-1; AltName: Full=Desmosomal glycoprotein 1; Short=DG1; Short=DGI; 
AltName: Full=Pemphigus foliaceus antigen; Flags: Precursor 
RecName: Full=Probable ATP-dependent RNA helicase DDX17; AltName: Full=DEAD box protein 17; 
AltName: Full=RNA-dependent helicase p72; AltName: Full=DEAD box protein p72 
replication protein A1  
retinoblastoma binding protein 7  
ribophorin I precursor  
RNA binding motif protein 39 isoform b  
Ro ribonucleoprotein  
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 12  
serum albumin  
siah binding protein 1  
splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated)  
splicing factor SF3a60  
suprabasin isoform 1 precursor  
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a5  
t-complex polypeptide 1  
testicular H1 histone  
thiol-specific antioxidant protein  
TLS protein 
topoisomerase I  
TR4 orphan receptor  
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transcription factor LSF  
transformation upregulated nuclear protein  
transglutaminase E3  
ubiquitin 
UV excision repair protein RAD23 homolog B  
vimentin  
Zn-alpha2-glycoprotein  
 
Table 2. Pull down- mass spectrometry results: the list of proteins which bound to the PCR 
product of LGALS4 upstream sequence, which contains C and G genotype (wild type). White 
box indicates common protein for wild and mutant types and orange boxes represent the unique 
proteins for each genotype. 
 
 
3.6. The expression of the binding proteins in different cell lines 
As a trial to correlate the presence of the SNPs, expression level of the binding proteins, 
and the expression of LGALS4, qRT-PCR was carried out for some selected genes in which 
their proteins are binding to LGALS4 upstream sequence. Therefore, 10 genes that are encoding 
the binding proteins (which were obtained by pull down-mass spectrometry results) were 
selected, either bound to the wild, the mutant-type, or both genotype of LGALS4 promoter as 
the following: ACO1, ENO1, FUBP1, FUBP2, HNRNPK, MYBBP1a, PRDX1, PUF60, RBBP7, 
and FUS. The qRT-PCR was done for the six cell lines (LT97, SW1116, SW480, SW620, 
CO115, and KM20L2) comparable to CCD-18Co (normal colon cell line). The experiment was 
done in three repeats and the results were normalized to GAPDH (figure 7). White box 
indicates common protein for wild and mutant types and orange boxes represent the unique 
proteins for each genotype. All of the mRNA of the investigated gene were expressed in 
CO115, which was consistent with the pull down-mass spectrometry results, since the CO115 
nuclear proteins were used. 
 
ACO1 
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ENO1 
 
 
 
FUBP1 
 
 
FUBP2 
 
 
HNRNPK 
 
 
 
 
 
 
 
 
 
 
 
Results 
32 
MYBBP1a 
 
 
PRDX1 
 
 
PUF60 
 
 
RBBP7 
 
 
FUS 
 
 
Figure 7. The qRT-PCR results of the genes, which encoding the binding proteins that bound 
to LGALS4 promoter sequence. 
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3.7. Methylation status 
In the present study, the CpG island was detected using Methprimer in the first exon 
and first intron. Accordingly, the primers for bisulfite sequencing were designed. After the 
bisulfite treatment, the PCR was performed and the methylation was detected by direct 
sequencing. Since the bisulfite treatment will convert the unmethylated cytocine to uracil, in 
the sequencing result the methylated cytocine will remain as it is, while the unmethylated 
cytocine will be thymine. As shown in figure 8b, the predicted CpG island of LGALS4 contains 
15 CG. The methylation status of six CG out of the 15 CGs were changed in colorectal cancer 
patients and cell lines samples, regarding the methylation status. In the cell lines exhibiting 
galectin-4 upregulation, LT97 and KM20L2 showed unmethylated pattern of the promoter 
region. Whereas, CCD18Co, SW1116, SW480, SW620, and CO115 exhibited methylated 
promoter (figure 8b).  
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Figure 8. Methylation status of LGALS4 promoter. a) The CpG island prediction and the 
primers for bisulfite sequencing using Methprimer. CpG island of LGALS4 contains 15 CG. 
The methylation status of six CG out of the 15 CGs were changing b) The bisulfite treatment 
will convert the unmethylated cytocine to uracil, in the sequencing result the methylated 
cytocine will remain as it is, while the unmethylated cytocine will be thymine. Accordingly, the 
bisulfite sequencing results of CpG island in galectin-4 promoter, LT97 and KM20L2 showed 
unmethylated promoter. While the other cell lines exhibited methylated upstream sequence. N 
represents heterogeneous peaks of C and T. 
 
 
3.8. Two SNPs are shown together in patient samples 
Among 115 samples collected from Germany and Egypt, we have found ss217320370 
C>A and G>A (rs73933062), both SNPs are present together in the same patient. Therefore, we 
called them twin SNPs. The direct sequencing of the upstream sequence of galectin-4 
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manifested the twin SNPs in 26 samples out of 115 patients (22.6 %) which are detailed as the 
following: 
1) Four out of 18 (22.2%) rectal cancer patients (table 3) from NCT, Heidelberg, 
Germany. 
 
 Sample 
no. ss217320370 rs73933062 age gender  
Grading T N M 
1 C/A G/A 66 M 2 4 0 X 
2 wt wt 71 M 2 3 2 1 (liver) 
3 wt wt 71 F 2 3 0 X 
4 wt wt 58 M 2 2 0 X 
5 wt wt 
53 M 3 4 1 1 liver 6 wt wt 
7 wt wt 56 M 2 2 0 X 
8 C/A  G/A 64 F 2 2 0 X 
9 C/A G/A 88 F 2 4 2 X 
10 wt wt 41 M 3 3 2 
1 (Liver, 
Lung) 
11 wt wt 60 M 2 3 1 X 
12 wt wt 53 F 2 3 1 X 
13 wt wt 67 M 2 3 0 X 
14 wt wt 57 M 2 3 0 X 
15 wt wt 78 M 2 2 0 X 
16 C/A  G/A 67 M 2 2 1 X 
17 wt wt 49 F 2 
two tumors 
3/1 2/2 X 
18 wt wt 68 F X 3 2 X 
 
Table 3. The sequencing results of galectin-4 upstream sequence in 18 rectal cancer patients, 
which were collected from tissue bank, NCT, Heidelberg. The results show, four patients 
display ss217320370 and rs73933062 together in the upstream sequence. 
 
 
2) 12 out of 54 patients (22.2%) showed the two SNPs in the lesion tissues and their 
adjacent normal tissue. The detailed results are as the following: 8 out of 27 (29.6%) 
tissue from colorectal cancer patients, 4/15 (26.7%) patients with ulcerative colitis, and 
0/12 with adenomatous polyps (ENCI, Cairo, Egypt). 
 
 
 
 No. lesion normal lesion normal          
  ss217320370 rs73933062 age gender location 
grade/grade of 
dysplasia 
1 C/A  C/A  G/A G/A 48 M Rectum II CRC 
2 wt wt wt wt 35 F rectum II 
3 wt wt wt wt 37 M rectum II 
4 wt wt wt wt 34 M sigmoid III 
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5 wt wt wt wt 52 F Ascending   n/a 
6 wt wt wt wt 38 F rectum II 
7 wt wt wt wt 47 F Ascending II 
8 wt wt wt wt 28 F rectum  II 
9  C/A   C/A  G/A G/A 60 M rectum I 
10 wt wt wt wt 38 F rectum I 
11  C/A   C/A  G/A G/A 55 F Descnding I 
12  C/A   C/A  G/A G/A 56 M rectum II 
13  C/A  C/A  G/A G/A 59 F rectum II 
14 wt wt wt wt 55 F rectum II 
15 wt wt wt wt 52 M caecum II 
16 wt wt wt wt 37 F rectum II 
17 wt wt wt wt 29 M sigmoid II 
18 wt wt wt wt 48 F Descnding III 
19  C/A   C/A  G/A G/A 64 F rectum II 
20 wt wt wt wt 30 F sigmoid  n/a  
21 wt wt wt wt 40 F rectum II 
22 wt wt wt wt 41 F sigmoid  n/a 
23 C/A  C/A  G/A G/A 46 M sigmoid  n/a 
24 wt wt     50   rectum   n/a 
25 C/A  C/A  G/A G/A 58 M Descnding   n/a 
26 wt wt wt wt 13 F rectum   n/a 
27 wt wt wt wt 35 M sigmoid   n/a 
28 C/A  C/A  G/A G/A 28 M UC No dysplasia UC 
29 wt wt wt wt 37 M 
recto-
sigmoid UC No dysplasia 
30 wt wt wt wt 74 M UC No dysplasia 
31 wt wt wt wt 45 M 
recto-
sigmoid UC No dysplasia 
32 C/A C/A  G/A G/A 30 M UC 
till splenic mild 
dysplasia 
33  C/A   C/A  G/A G/A 69 M 
whole 
splenic UC No dysplasia 
34 wt wt wt wt 27 F 
recto-ileum 
UC No dysplasia 
35 wt wt wt wt 17 F  whole UC dysplasia 
36  C/A   C/A  G/A G/A 38 M whole UC No dysplasia 
37 wt wt wt wt 50 M whole UC y moderate 
38 wt wt wt wt 43 M left UC No dysplasia 
39 wt wt wt wt 60 F rectum UC dysplasia 
40 wt wt wt wt 65 F 
Up to 
transvrese 
UC 
Marked 
dysplasia 
41 wt wt wt wt 30 M 
recto-
sigmoid UC No dysplasia 
42 wt wt wt wt 55 M left UC No dysplasia 
43 wt wt wt wt 60 M Transverese   polyps 
44 wt wt wt wt 69 M 
transverese 
polyps   
45 wt wt wt wt 50 F 
hepatic 
polyps   
46 wt wt wt wt 39 F 
Transverse 
polyps   
47 wt wt wt wt 45 F 
Ascending 
polyps   
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48 wt wt wt wt 50 M 
sigmoid 
polyps   
49 wt wt wt wt 35 M 
sigmoid 
polyps   
50 wt wt wt wt 54 M 
Descending 
polyps   
51 wt wt wt wt 56 M 
sigmoid 
polyps   
52 wt wt wt wt 52 M rectal   
53 wt wt wt wt 50 M 
cecum 
polyps   
54 wt wt wt wt 45 M 
sigmoid 
polyps   
 
Table 4. The sequencing results of galectin-4 upstream sequence in 54 patients with colorectal 
cancer, ulcerative colitis (UC), or colorectal polyps, which were collected from ENCI. Twelve 
out of 54 showed ss217320370 and rs73933062 together in galectin-4 promoter. Interestingly, 
the two SNPs were found in the lesion tissue (biopsy from tumor, UC area, or polyps) and the 
adjacent normal in all of the twelve patients. 
 
 
3) Two out of 15 (13.3%) colorectal tumors and premalignant lesions from ENCI, Cairo, 
Egypt. The DNA samples were obtained from the lesion (tumor, or the premalignant 
lesion), but the adjacent normal tissues were unavailable. 
 
no.  ss217320370 rs73933062 Age gender Type of cancer 
1 wt wt 30 M Known patient for cancer rectum with 
suspecious recurrence. Mild non specific 
inflammation 
2 wt wt 57 F anorectal cancer (malignant primary site , 
single tumor) grade 3. Poorly 
differentiated adenocarcinoma. Patient 
has metastasis in the adrenal gland 
3 wt wt 29 F rectal adenocarcinoma grade 2 (lymph 
node -ve) 
4 wt wt 65 M Recto segmoid adenocarcinoma, grade 2 
(Duke's D) 
5 wt wt 58 F rectal adenocarcinoma grade 2 
6 wt wt 43 F rectosegmoid junction adenocarcinoma 
grade 3 
7a,b wt wt 64 F colon rectal multiple tumors, 
adenocarcinoma grade 2 
8 wt wt 43 M rectal adenocarcinoma grade 2 
9 wt wt 58 M rectal, tubulovilous adenoma with severe 
dysplasia 
10 wt wt 31 F colon adenocarcinoma grade 2 
11 wt wt 61 M peritoneum, metastastatic recurrence of 
mucinous adenocarcinoma 
12 wt wt 35 M ulcerative colitis with inflammatory 
pseudo polyp 
13 C/A G/A 57 F anal canal, adenocarcinoma, grade 2 
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14 wt wt 57 M rectal adenocarcinoma grade 2 
15 C/A G/A 46 F rectum, multicentric adenocarcinoma, 
grade 2 
 
Table 5. The sequencing results of LGALS4 promoter in 15 tissue samples of colorectal 
diseases. Two out of 15 tissue samples showed ss217320370 and rs73933062 together in the 
upstream sequence. 
 
 
4) Eight out of 28 (28.6%) in blood samples of gastrointestinal tumors. 
 
no.  ss217320370 rs73933062 Age Diagnosis  
1 C/A  G/A 57 rectal carcinoma grade II 
2 wt wt 67 colon adenocarcinoma grade II 
3 wt +G/A G/A 36 pancreatic pseudo papillary tumor 
4 wt wt 57 multiple tumors in ovaries, mesentry, bladder 
5 C/A  G/A 58 
Scanty, fragmented consistent with metastatic carcinoma in 
lymph node  
6 wt wt 53 hepatocellular carcinoma  
7 wt wt 51 sigmoid colon adenocarcinoma grade 
8 wt wt 58 rectal invasive adenocarcinoma grade 2 negative 
9 wt wt 62 
gall badder adenocarcinoma and Overctomy, bilateral ovarian 
serous cyst adenocarcinoma 
10 C/A  G/A 54 rectal cancer grade II 
11 C/A  G/A 52 mild chronic colitis 
12 wt wt 63 hepatocellular carcinoma  
13 wt wt 43 colon adenocarcinoma recurrence 
14 wt wt 57 stomach carcinoma 
15 wt wt 52 oesophagus, hyperplastic squamous epithelium 
16 C/A  G/A 62 hepatocellular carcinoma  
17 wt wt 64 rectum, tubulovillous adenoma 
18 wt wt 37 desending colon adenocarcinoma grade  
19 wt wt 30 recto-sigmoid junction, mild chronic non specific colitis 
20 wt wt 43 colon, multicentric adenocarcinoma 
21 wt wt 40 rectum, mucinous adenocarcinoma 
22 C/A  G/A 44 colon  ulcerative colitis 
23     57 anal canal, adenocarcinoma grade 2 
24 wt wt 58 rectum, tubulovillous adenoma with severe dysplasia 
25 C/A  G/A 30 rectal adenocarcinoma 
26 wt wt 46 rectum, multicentric adenocarcinoma grade 2 
27 wt wt 61 
colon inflammation and peritoneum metastatic recurrence of 
mucinous adenocarcinoma 
28 wt wt 69 
metastatic adenocarcinoma of lung, breast, gastrointestinal 
tract, female genital 
 
Table 6. The sequencing results of LGALS4 promoter in blood samples of gastrointestinal 
tumors. Eight out of 28 blood samples showed ss217320370 and rs73933062 together in the 
upstream sequence. 
  
3.9. Galectin-4 is upregulated in colorectal cancer patients 
The mRNA of 26 patients was available in good quality. Thus, the qRT-PCR was 
carried out for these samples to investigate galectin-4 regulation in CRC patients in comparison 
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to normal colon. The results were normalised to GAPDH as a housekeeping gene.  
Surprisingly, 25 cases out of 26 showed upregulation in the mRNA level of LGALS4 with 
different range of fold change (figure 9). Mere one samples exhibited downregulation in 
galectin-4 comparable to the normal control. 
 
 
 
 
 
 
Figure 9. qRT-PCR results of 26 CRC patients. Out of the twenty-six patient, 25 cases showed 
upregulation in the mRNA level of galectin-4. Only one sample was downregulated among the 
twenty-six patients. 
 
 
 
3.10. galectin-4 upregulation is associated with promoter methylation in the 
colorectal cancer patients 
Only twenty samples were with enough quantity of DNA for bisulfite treatment. 
Therefore, in order to correlate mRNA expression and methylation status of CpG island 
galectin-4, twenty samples out of 26 with known galectin-4 expression were sequenced after 
the bisulfite treatment. All of those twenty samples showed mRNA upregulation of galectin-4. 
Also, the two SNPs were detected in three of these samples. Surprisingly, 17 patients showed 
methylated CpG island, which was associated with mRNA upregulation. Just three samples out 
of the twenty showed unmethylated promoter. Among the three unmethylated samples, one 
patient (number 7 as shown in table 5) has two tumors, one of them showed unmethylated CpG 
and second tumor exhibited methylated promoter of galectin-4. whereas, both tumor with 
unmethylated and methylated CpG islan in this patient showed upregulated mRNA level of 
LGALS4 with 789 and 841 fold change respectively. 
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rs73933062  ss217320370 rs73933062 
fold 
change   gender  age  Diagnosis 
1 wt  2.205 methylated M 30 
Known patient for cancer rectum with suspecious recurrence. 
Mild non specific inflammation 
2 wt wt 85.46 methylated F 57 
anorectal cancer (malignant primary site , single tumor) grade 
3. Poorly differentiated adenocarcinoma. Patient has metastasis 
in the adrenal vgland 
3 wt wt 1008 methylated F 29 rectal adenocarcinoma grade 2 (lymph node -ve) 
4 wt wt 294.7 unmeth M 65 Recto segmoid adenocarcinoma, grade 2 (Duke's D) 
5 wt wt 384.5 
 
methylated F 58 rectal adenocarcinoma grade 2 
6 wt wt 513.3 methylated F 43 rectosegmoid junction adenocarcinoma grade 3 
7a wt wt 789.4 unmeth  
F 64 colon rectal multiple tumors, adenocarcinoma grade 2 7b wt wt 841.4 
 
methylated 
8 wt wt 930.7 
 
methylated M 43 rectal adenocarcinoma grade 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   ss217320370  rs73933062         Grading T N M 
NCT 
1 C/A at -233 G/A 9.017 
methylated 
M 66 2 4 0 X 
NCT 
2 wt wt 21.12 
methylated 
M 71 2 3 2 1 (Hep) 
NCT 
3 wt wt 29.76 
methylated 
F 71 2 3 0 X 
NCT 
4 wt wt 4.096 
methylated 
M 58 2 2 0 X 
NCT 
5 wt wt 28.64 unmeth M 53 3 4 1 1 hepatic 
NCT 
6 wt wt 5.446 
methylated 
            
NCT 
7 wt wt 11.61 
methylated 
M 56 2 2 0 X 
NCT 
8 C/A at -233 G/A 4.581 
methylated 
F 64 2 2 0 X 
NCT 
9 C/A at -233 G/A 8.703 
methylated 
F 88 2 4 2 X 
NCT 
10 wt wt 5.906 
methylated 
M 41 3 3 2 
1 (Liver, 
Lung) 
NCT 
11 wt wt 151.7 
methylated 
M 60 2 3 1 X 
NCT 
12 wt wt 2.257 
methylated 
F 53 2 3 1 X 
Table 7. The results of promoter sequencing, methylation status, and qRT-PCR of galectin-4 of 
twenty colorectal cancer patients.  
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Discussion 
 
The overall 5-year survival rate from colon cancer has increased due to the early 
detection from increased screening. Most CRCs arise from adenomatous precursors and 
accumulation of mutations in proto-oncogenes and tumor suppressor genes (TSGs) leads to 
progression of adenomatous lesions to carcinoma [3,4,5]. High-throughput expression and 
genotyping arrays are starting to generate novel markers and gene signatures that may be of use 
in the management of colorectal cancer. However, at present, these are not sufficiently 
validated to be clinically useful [6]. 
 
In the present study, in order to get a gene expression profile overview for early and late 
stages of colorectal cancer, we have profiled the expression of different Duke’s stages of 
colorectal cancer cell lines.  Surprisingly, the correspondence analysis of the expression 
profiling showed a convergence between the benign polyposis cell line (LT97) and Duke’s D 
stage cell line (KM20L2). LT97 is an early stage of tumor development and derived from early 
adenoma cells from microadenomas of patient suffering from hereditary familiar polyposis 
[87]. Thus, far from tumor classification, the expression profiling results differentiate between 
good and bad prognosis. Therefore, tracing the differentially regulated genes in LT97 and 
KM20L2 could be a promise to establish new prognostic markers. Therefore, it was interesting 
to focus on a gene, which is regulated in the cell lines with proposed bad prognosis aspects (in 
this study, LT97 and KM20L2 were the candidate of poor prognosis).  
 
Among more than 400 genes that were filtered from analysis of the microarray results, 
there were several genes were showing differential expression in LT97 and KM20L2. From the 
literature, interestingly, galectin-4 is expressed in gastrointestinal tissues but not in kidney, 
brain, skeletal muscles, heart, liver or lung tissues [11]. In our expression profiling data, we 
have found that galectin-4 was among the genes that are significantly upregulated in LT97 and 
KM20L2 and not in the rest of cell line, which may give an indication that galectin-4 could 
have a role in tumor progression or invasion. Consistently, in a previous study, upon expression 
of galectin-4, epithelial cells acquired a phenotype characterized by the ability to survive lack 
of nutrients and growth factors for the prolonged period of time. Thus, this cellular phenotype 
is likely to be advantageous in hyperplastic tissues of premalignant and malignant tumors [11]. 
The association of poor prognosis of cancer and galectin-4 upregulation is previously reported 
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[59], which was consistent with our results and interpretation. Moreover, in the present study, 
among the mRNA of 26 colorectal cancer patient samples that were investigated by qRT-PCR, 
galectin-4 was found to be upregulated in 25 patients. Therefore, it was interesting to go deeply 
in galectin-4 regulation via promoter study (from the genetic and the epigenetic aspects). 
 
The direct sequencing results of 0.7 kb of galectin-4 upstream sequence revealed two 
SNPs; a previously known SNP rs73933062 and SNP at contig 11572034 C/A. Moreover, the 
two SNPs were found together in the two cell lines, which are upregulating galectin-4 (LT97 
and KM20L2). Hence, this gave us the suggestion that two SNPs could influence the promoter 
activity. rs73933062 is located in the first intron after the TSS, which could be in the putative 
enhancer sequence. It is encoded in the mRNA but not translated to a protein. However, 
rs73933062 is not previously reported for clinical association. SNP at contig 11572034 C/A is 
not previously annotated and we have submitted it as ss217320370. It is located before the 
TSS; therefore, it could be in the putative distal promoter. 
 
 To investigate the frequency of the two SNPs in colorectal cancer patient and also 
whether the two SNPs are together as a genotype in the same individual, we have sequenced 
the upstream sequence of 115 patients collected from NCT, Heidelberg, Germany and ENCI, 
Cairo, Egypt. In total 26 out 115 patients showed the two SNPs together (ss217320370 
(11572034 C>A) and G>A which is known as rs73933062) as the following: Four out of 18 
(22.2%) colorectal cancer patients from NCT, Heidelberg, Germany, 12 out of 54 patients 
(22.2%) showed the two SNPs in the lesion tissues and their adjacent normal tissue (8 out of 27 
(29.6%) tissue from colorectal cancer patients, 4/15 (26.7%) patients with ulcerative colitis, and 
0/12 with adenomatous polyps from ENCI, Cairo, Egypt), Two out of 15 (13.3%) colorectal 
tumors from ENCI, Cairo, Egypt,  and 8/28 (28.6%) in blood samples of gastrointestinal 
tumors. Conclusively, the two SNPs were showed always together in 26 out of the 115 (22.6%) 
patient samples. 
 
The two SNPs influenced the promoter activity. To conclude that, the upstream 
sequence has been cloned in luciferase reporter plasmid (pGL4.10) and transfected to Co115 
cell line. As a result, the luciferase reporter of the upstream sequence containing either one of 
the two SNPs or both showed significant upregulation of the promoter activity comparable to 
normal genotype. The presence of mere rs73933062 in the luciferase construct showed 1500 
fold change in the luciferase activity with p-value 0.002. To validate the huge fold change 
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increase of luciferase activity in case of rs73933062, two more cell lines were transfected 
(SW1116 and Sw620) with the luciferase construct with the investigated SNP. Interestingly, the 
presence of rs73933062 also caused an increase in the luciferase activity with 37 and 36 fold 
changes in SW1116 and SW620 respectively. Transfecting CO115 with luciferase construct 
that contains ss217320370 showed a mild change in the luciferase activity, 1.3 fold change with 
0.03 p-value. The combination of ss217320370 and rs73933062 increased the promoter activity 
four times with 0.004 p-value. From the insight, we thought that the combination of the two 
SNPs will increase the promoter activity by value bigger than the presence of solitary SNP. 
However, the results showed that the combination of the two SNPs increased the promoter 
activity with a value less than 1500 that caused by rs73933062 alone, for instance. That could 
be referred to the distance between the two SNPs, which could contain silencer binding site. 
 
Our results showed that the presence of ss217320370 and rs73933062 changed the 
transcription factors binding site. The verification of this result was carried out by using the 
upstream sequence as bait for protein pull down followed by mass spectrometry. The results 
showed the general binding proteins that bind to both genotype and some unique proteins for 
each genotype. Therefore, pull down results support the luciferase reporter assay results. Thus, 
the two variations caused deletion and insertion of regulatory protein binding sites. Basically, 
the upstream sequence of galectin-4, regardless to the genotype does it have, binds to 
transcription factors such as FUBP1, FUBP2 , FUS, LBP-1a, ENO1, and TFCP2. 
 
As mentioned above, each genotype variant binds to some unique proteins in addition to 
basic binding regulatory proteins. Among the distinctive proteins of those binders that tethered 
to genotype containing C and G at the contig position 11572034 and 11571652 respectively: 1) 
Aconitase 1 (ACO1), also known as iron regulatory element binding protein 1 (IREB1), is a 
cytosolic protein which regulate ferritin mRNA via its binding to iron-responsive elements 
(IREs). Therefore, its binding to IREs results in repression of ferrit -UTR mRNA [88]. 
Since G at the contig position 11571652 is transcribed and included in the mRNA sequence but 
not translated, the pull down of ACO1, in the case of G at the contig position 11571652, could 
indicate that galectin-4 is negatively regulated by ACO1 via pre-mRNA. 2) RBBP7 
(retinoblastoma binding protein-7) which is found previously among several proteins that binds 
directly to retinoblastoma proteins that regulate the cell proliferation. The encoded protein is 
found in many histone deacetylase complexes [89,90]. It is also known by limiting the 
expression of estrogen-responsive genes [91]. 3) PUF60 (poly-U binding splicing factor 60 
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Kda) or also known as FIR (FBP Interacting Repressor): the protein forms a tenary complex 
with far upstream element (FUSE) and FUSE-binding proteins. It can repress a c-myc reporter 
via the FUSE. Also, it is known to target transcription factor IIH and inhibits activated 
transcription [92]. Since the upstream sequence of galectin-4 binds to FUBP1 and FUBP2 
regardless to the variations, binding to PUF60 (in the case of C and G at the contig position 
11572034 and 11571652 and not A and A at those two position) is supporting the luciferase 
reporter assay.  In other word, PUF60 could repress galectin-4 promoter via binding FUSE-
binding proteins. 4) Several other proteins with numerous functions ranging from transcription 
activation to repression such as BAT1, CGI-46, chromatin assembly factor-1 subunit B, DAZ 
associated protein-1. 
 
On the other hand, in the case of C>A at position 11572034 and G>A at position 
11571652, the two SNPs are inserting new binding sites for regulatory proteins such as: MYB 
binding protein-1a which is a transcription factor. It is a member of SRC/p160 gene family and 
has been known as a coactivator [93]. However, it is also previously investigated as a novel co-
repressor of NF-ĸB [94]. In addition, some other proteins are binding to the two SNPs (C>A at 
position 11572034 and G>A at position 11571652). Some of those proteins are not previously 
known as DNA-interacting proteins such as PRDX1, fatty acid binding protein-5 (FABP5), 
apolipoprotein D, and squamous cell carcinoma antigen. 
 
In conclusion, from pull down - mass spectrometry results, it seems that changing of 
single nucleotide, is mostly deleting repressor binding site(s) rather than inserting new 
effectively transcriptional activating proteins. Activating or repressing function should be more 
investigated in the future research. 
 
Since the two SNPs are influencing the binding sites for DNA-binding proteins, also the 
regulation of the TFs are influencing the promoter activity. For instance, if a given transcription 
silencer binds to a promoter and this silencer is downregulated or not expressed in the cells. In 
this case, it makes no sense if this silencer is binding to the promoter or not, since it is not 
expressed in the cells. To correlate the expression of the transcription factors (which bind to the 
either wild or mutant type promoter) and the expression of galectin-4, qRT-PCR was done for 
ten genes that are encoding the binding proteins. Among those proteins, for instance, ENO1 
which we found to bind to galectin-4 promoter in the presence or the absence of the twin SNPs, 
is known previously, in terms of function, as transcription repressor [95,96]. The mRNA 
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expression of ENO1 was upregulated in five out of six cell lines. The only cell line which 
didn’t show ENO1 upregulation is LT97, which could be correlated with the upregulation of 
galectin-4 in this cell line, since the ENO1 is a transcriptional repressor. Another example, 
RBBP7, is found in many histone deacetylase complexes, including mSin3 co-repressor 
complex. It is also present in protein complexes involved in chromatin assembly [97]. Also, in 
the qRT-PCR results, RBBP7 was found to be upregulated in all cell lines. RBBP7 bound to 
the wild type promoter and not in the presence of the SNPs which showed by pull down-mass 
spectrometry results. Therefore, the expression of RBBP7 in LT97 and KM20L2 might not 
influence the promoter activity and hence the gene expression, since the two cell line have 
ss217320370 and rs73933062. However, the overexpression of RBBP7 could give a clue to 
interpret the downregulation of galectin-4 in SW1116, SW480, SW620, and CO115, since it 
could function as co-repressor. The qRT-PCR results for ten selected genes, which are 
encoding the binding proteins, didn’t give a concrete base to understand the mechanism of each 
binding protein whether they activate or suppress galectin-4 expression, even with the previous 
knowledge of each protein function. However, since we used CO115 nuclear protein in the pull 
down experiment, the qRT-PCR results for the selected genes in CO115 cell line could be 
positive control for pull down-mass spectrometry analysis, since all genes were upregulated in 
CO115. 
 
The CpG island was predicted in the first exon and the first intron. The methylation 
status of galectin-4 promoter in the cell lines was consistent with the qRT-PCR results. So, 
LT97 and KM20L2 with upregulated galectin-4 showed unmethylated promoter. Whereas, the 
rest of the cell lines (SW1116, SW480, SW620, and CO115) showed methylated promoter. In 
colorectal cancer patients, the situation is much more complicated. While the twenty samples 
that have been investigated for methylation status were upregulating galectin-4, just three 
samples exhibited unmethylated promoter and the rest were methylated. Three out of the 17 
methylated samples have the two SNPs. In these three samples with the two SNPs and 
methylated promoter, the galectin-4 upregulation could be referred to the presence of the two 
SNPs as discussed earlier regarding the effect of ss217320370 and rs73933062 on the promoter 
activity. On the other hand, 14 samples were found with upregulated galectin-4 and methylated 
promoter, in parallel, they don’t contain ss217320370 and rs73933062.  In this case (promoter 
methylation and no SNPs to activate the promoter), the methylation might play a role in 
preventing repressor(s) proteins from the binding to their response element in the promoter 
sequence. Therefore, methylation could be a mechanism to activate the galectin-4 promoter and 
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subsequently increase the gene expression, but it needs more investigation in the future 
research.  
 
In conclusion, in the present study, galectin-4 upregulation was detected in most of 
colorectal cancer patient and two cell lines with potential susceptibility to develop colorectal 
cancer (LT97) and the Duke’s D cell line (KM20L2), which could indicate a prognostic value 
of galectin-4 in colorectal cancer. The twin SNPs (ss217320370 and rs73933062) in the 
upstream sequence and the first intron were associated with upregulation of the galectin-4, 
which could be referred to changing in the protein binding site according to our pull down- 
mass spectrometry results. Therefore, the twin SNPs could have a medical impact in cancer via 
galectin-4 upregulation. Also, methylation was not found to be a mechanism for galectin-4 
downregulation.  
 
Outlook 
 
Recently, an interaction was found between galectins and the blood group antigens. 
ABO(H) blood group antigens are composed of carbohydrate structures that only differ by 
distinct monosaccharides on the terminal structures of glycans [98]. Human galectin-3, -4, and -
8 were shown to recognize multiple glycan structures [78,99]. In a recent study, it was also 
shown that galectins recognize blood group-positive bacteria and hence play a role in the innate 
immunity. Moreover, it has been reported that galectin-3, -4 and -8 bind specifically to blood 
group A and B at submicromolar concentrations but not to blood group O (H) [79].  
 
By combination of the above-mentioned facts, we postulate that galectins enable 
circulating tumor cells, which are responsible for metastasis formation, to interact with red 
blood cells that are carrying a blood group antigen. We performed pilot experiments to check 
the validity of our assumption and the results support the hypothesis, although they are only 
preliminary in nature. Thus, we are aiming at an investigation of the functional aspects of 
galectin upregulation in cancers with bad prognosis and an analysis of their role in stabilizing 
circulating tumor cells by interaction with erythrocytes (figure 10). 
 
In a preliminary analysis, we have looked at the interaction of blood and tumor cells and 
its effect on the tumor cells. In previous studies, we had found that galectin-4 showed 
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significant up-regulation in KM20L2, a Duke’s D tumor cell line. KM20L2 was then used to 
study possible interactions of tumor cells that up-regulate galectin-4 and erythrocytes.  
 
 
 
 
Figure 10. Schematic representation of the results of the pilot study. Tumor cells that exhibit 
up-regulation of galectins (LGALS) 3, 4, and 8 interact with red blood cells (RBCs), if blood of 
antigen group AB is used. Galectins accumulate at the sites of attachment to the erythrocytes. 
 
    
We obtained blood from healthy individuals with blood groups AB and O. About 
100,000 erythrocytes were added to 10,000 KM20L2 cells and incubated. Then, the respective 
mixture was smeared on glass slides and stained with haematoxylin-eosin or immunostained 
using a galectin-4 antibody. In the immunostaining, galectin-4 was found to occur 
predominantly at the cell membrane locations, which were in contact with the erythrocytes 
(figure 11).  
 
In another experiment, KM20L2 cells were incubated with erythrocytes from blood 
group AB, in parallel to KM20L2 cells without blood cells. The live cells were observed with a 
Zeiss cell observer for five hours. Every two minutes, a picture was taken. At the end of the 
experiment, the recorded pictures were analyzed using the Axiovision documentation (Zeiss) 
and a video of the cellular interactions was obtained. The interactions of tumor cells and 
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erythrocytes started during the first 30 mins. Eventually, the cells separated again after 90-120 
min; this is probably due to galectin-4 secretion and saturation of the erythrocyte membrane 
with the secreted galectin-4. 
 
When KM20L2 cells were incubated without erythrocytes, the tumor cells underwent 
apoptosis. From these experiments and the known functions and association of galectin-4 with 
tumors, we postulate that the erythrocytes are serving as a substrate for tumor cell anchorage 
and that this interaction prevents their apoptosis while circulating in the blood. This 
phenomenon could be of great interest for understanding how to destabilize circulating tumor 
cells and thus to target metastasis formation.  
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Figure 11. Staining of mixtures of tumor cell and erythrocytes. Staining was with 
haematoxylin & eosin (H&E, a-d) and by galectin-4 immunostaining (e-g) using blood of AB 
and O groups. In the case of AB-blood, there was an obvious binding between the tumor cells 
and the erythrocytes. Interestingly, galectin-4 protein was accumulated at the cell membrane 
locations of the tumor cells that were in contact to erythrocytes. This could indicate chemotaxis 
to blood group antigen. In case of blood group O, galectin-4 protein was evenly distributed in 
the cell membrane. 
 
 
  
 
 
 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part II: Setting up Transcription Factor Protein Array Detecting DNA-
Protein Interactions 
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1. Introduction 
 
Determination of the sequence of the human genome and knowledge of the genetic code 
has allowed rapid progress in the identification of mammalian proteins. However, far less is 
known about the molecular mechanisms that control expression of human genes and about the 
variations in gene expression that underlie many pathological states, including cancer. This is 
caused in part by lack of information about the binding specificities of DNA-binding proteins 
and particularly regulative important molecules such as transcription factors (TFs). It is 
consequently crucial to develop technologies for the detection of DNA-protein interaction in 
order to identify DNA response elements and the related transcription factors or other DNA-
binding proteins. The techniques vary with respect to the type of result that can be expected 
from the assay: a mere qualitative demonstration of binding; the identification of response 
element sequences at high-throughput; or a quantitative characterisation of affinities. 
 
For many years, biochemical processes were used to characterise DNA-protein 
interactions. However, such approaches are generally laborious and slow. Recent decades have 
witnessed the development of technologies that permit analyses at a larger scale and in a more 
unbiased manner. These approaches are often either gene-centred or protein-centred [100]. In 
gene-centred approaches, an individual protein is used to identify DNA target sequences. 
Inversely, an individual DNA sequence is used to identify and study the relevant DNA binding 
proteins in a protein-centred assay. Recently, microarray and sequencing technology were 
employed toward genome-wide analyses in both formats. As a result of these developments, 
more and more regulatory elements and factors are uncovered. In consequence, there is a 
continuously growing understanding of many basic regulatory processes that involve DNA-
protein interaction.  
 
In the present study, a suitable condition was optimised to pursue DNA-protein 
interaction on chip. For this purpose, the transcription factor proteins were expressed, purified, 
and spotted on appropriate surface and subsequently incubated with target DNA sequences.  
Introduction 
52 
 
1.1. DNA-protein interaction 
Wide ranges of proteins are crucial for successful transcription by RNA polymerase in 
eukaryotic cells via binding to the cis-regulatory elements, such as promoters and enhancers.  
These proteins include general transcription factors, co-factors, histones, chromatin 
remodelling proteins, and sequence-specific transcription factors that direct transcription 
initiation to specific promoters [101,102,103].  
 
Promoters consist of common sequence elements, such as a TATA box and an initiator 
sequence, and binding sites for other transcription factors, which work together to recruit the 
general transcriptional machinery to the transcriptional start site (TSS). Enhancers are located 
some distance from the site of transcription initiation and also contain binding sites for 
transcription factors. Transcriptional activity from general factors binding to the core promoter 
is usually low, but the binding of site-specific factors to proximal promoter regions can 
increase it. Promoter activity can be further stimulated by the binding of factors to distal 
enhancer regions and the subsequently recruit histone-modifying enzyme that creates a more 
the proper chromatin environment for transcription or of a kinase that induces a bound 
initiation complex to begin elongation. Repressive factors bind also to silencing sequence far 
from the TSS, which can interfere with activator binding [102,104,105]. 
 
The location relative to the TSS, at which a factor binds, is of interest, since it can 
provide insight into the mechanisms by which the factor regulates transcription. In other words, 
factors that bind close to TSS have been proposed to regulate transcription by stabilizing 
general transcription factors at the core promoter elements. On the other hand, factors that bind 
to distal regions, either upstream or downstream of a gene, may regulate transcription by 
mediating, through a looping mechanism, the protein–protein contacts between distal 
complexes and the general transcriptional machinery bound at TSS. Therefore, comprehensive 
analysis of the binding locations of a factor not only allows the development of a genomic map 
but also provides insight into the mechanisms for how this factor regulates transcription [104]. 
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1.2. Analysis of DNA-protein interactions; from nitrocellulose filter-binding 
assays to microarray studies 
 
1.2.1. Nitrocellulose filter-binding assay 
This assay was developed in the early stages of molecular biology in the 1970s. The 
manipulations are rapid enough to allow kinetic studies as well as equilibrium measurements 
[106,107,108]. The process is based on the fact that proteins bind to nitrocellulose without 
loosing their DNA-binding capacity, while double-stranded DNA alone is not retained. For 
analysis, DNA and proteins are mixed and incubated under appropriate conditions. The mixture 
is then separated by electrophoresis and subsequently blotted onto nitrocellulose. Since only 
proteins bind, DNA remains on the membrane only if in complex with a protein. The exact 
amount of DNA that is stuck to the nitrocellulose can be quantified by measuring a label that is 
introduced to the DNA prior to incubation with the protein. The amount of information 
obtained from this kind of assay is limited, however. Only the mere retention of labelled 
nucleic acid is detected and not the identity of the proteins involved or the proportion of 
binding activity attributable to an individual protein, if more than one protein in the mixture 
exhibits DNA-binding capacity [109]. Moreover, as a technical complication, single-stranded 
nucleic acids are retained at nitrocellulose filters under particular conditions, resulting in 
background that can obscure the measurement [110].  
 
1.2.2. DNase I fingerprinting 
Fingerprinting assays (figure 12) exploit the fact that a protein, which is bound to a 
specific nucleic acid, will interfere with a chemical or enzymatic modification of that DNA-
fragment. Thus, the modification can be used to localise the contact area between protein and 
DNA [111]. For the DNase I fingerprinting assay [112,113], a particular DNA-fragment is 
labelled at one end and mixed with the protein of interest. Following binding, the DNA is 
treated with the enzyme deoxyribonuclease I (DNase I), which digests DNA that is not in close 
contact to a protein and thus not protected from digestion. Performing a partial cleavage 
without protein produces labelled DNA-fragments that – because of the random nature of 
cleavage – cover the entire size range of the original DNA. In the presence of a binding protein, 
however, protection occurs in a particular region and labelled DNA-fragments of the respective 
length are not produced, while all longer or shorter ones are still present. Resolving the two 
samples on a polyacrylamide gel side by side, the differences in the resulting ladders of DNA 
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bands is visualised via the incorporated label. Gaps in the band ladder of the sample, in which 
protein had been present, indicate binding sites. Comparison of the patterns with sequencing 
reactions allows the identification of protected sequences with single-nucleotide resolution. 
 
 
 
Figure 12. Schematic representation of DNase I footprinting. Further details on the process are 
given in the text. 
 
1.2.3. Dimethyl sulphate (DMS) protection fingerprinting 
DMS protection fingerprinting is a chemical variant of the enzymatic DNase I 
fingerprinting and relies on the ability of DMS to methylate specifically guanine residues in 
DNA. The methylated G residues are cleaved by exposure to piperidine, whereas no cleavage 
occurs at unmethylated bases [114]. A protein bound to a DNA will protect the G residues from 
methylation and hence from cleavage by piperidine. 
 
1.2.4. Electrophoretic mobility shift assay (EMSA) 
In comparison to the assays described above, EMSA is a relatively rapid method to 
detect particular DNA-protein interactions [115,116]. It relies on the fact that the 
electrophoretic mobility of a complex of nucleic acid and protein is less than that of the free 
nucleic acid. Mobility-shift assays are often used for qualitative purposes. However, under 
Introduction 
55 
appropriate conditions, they can even provide quantitative data for the determination of binding 
stoichiometries, affinities and kinetics. The exact methods used differ for each purpose as 
reviewed elsewhere [117,118]. Despite of the fact that the technique is widely used to detect 
DNA-protein interactions, it has several limitations. Rapid dissociation during electrophoresis 
can prevent detection of complexes. Also, many complexes are significantly more stable in a 
gel than they are in free solutions [119]. In addition, EMSA is not informative about the 
sequences of the nucleic acids that are bound by the proteins. Another limitation is the fact that 
the observed mobility shift does not provide a direct measure of the molecular weight or 
identity of the proteins responsible. However, modifications such as an electrophoretic 
supershift assay and procedures that combine EMSA with Western blotting or mass 
spectrometry have been designed to identify the DNA-binding proteins [118]. 
 
1.2.5. Methylation interference assay 
This procedure is also based on the ability of dimethyl sulphate (DMS) to methylate G 
residues, which in turn are cleaved by piperidine [114] and the fact that methylation of purine 
residues in a DNA sequence inhibits formation of a DNA-protein complex [120,121]. For the 
assay, an end-labelled DNA probe is partially methylated with DMS and incubated with a 
nuclear protein extract. The protein-DNA complexes formed during the incubation are then 
separated from the free DNA using EMSA. Both the protein-bound DNA and the free DNA are 
eluted from the gel, cleaved with piperidine and again resolved by denaturing polyacrylamide 
gel electrophoresis. If methylation had occurred at a particular guanine residue that is critical 
for the DNA-protein interaction, the binding of the protein to that DNA was inhibited, resulting 
in the recovery of the DNA only from the free DNA fraction. The presence of particular DNA-
fragments in the free DNA fraction and their concomitant absence from the DNA-protein 
fraction indicates that those nucleotides are contact points of proteins. 
 
1.2.6. Chromatin immunoprecipitation (ChIP) 
ChIP is a method to identify DNA-protein complexes that occur in vivo and currently 
the standard method for the identification of histone modification locations and transcription 
factor binding sites [122]. Cells are initially treated with a cross-linking agent to link covalently 
any DNA-binding protein to the chromatin. Then, the cells are lysed and the genomic DNA is 
isolated and sonicated to produce sheared chromatin. An antibody specific to the protein of 
interest is added to the sonicated material and used to isolate the protein with all attached DNA 
via immunoprecipitation. The DNA is released by reversing the cross-linking and purified 
Introduction 
56 
subsequently. Classically, the DNA obtained from ChIP reactions was assessed by PCR, details 
of which are reviewed elsewhere [123]. In combination with hybridisation microarrays (ChIP-
on-chip), the assay became much more powerful, identifying the binding sequence and its 
location in the genome by hybridisation to a particular array feature [124]. ChIP-seq is a more 
recent alternative, using second generation DNA sequencing instead of microarray technology 
for sequence identification [125]. In any combination, ChIP has several inherent features that 
can make the identification of DNA-binding sites difficult. Particularly lacking specificity of 
the DNA-binding protein or the antibody used for precipitation can result in an experiment with 
insufficient enrichment [126].  
 
1.2.7. DNA adenine methyltransferase identification (DamID) 
Like ChIP, DamID is an assay to detect DNA-protein interactions in vivo. The target 
protein is expressed as a fusion molecule with DNA adenine methyltransferase (Dam) 
originally expressed in E. coli. Dam methylates the adenine of a GATC site. Therefore, when 
the fusion-protein binds to DNA, the Dam portion will methylate GATC sites that are located 
in the vicinity of the binding sites. The methylated sites in the target DNA and a control sample 
(expression of Dam alone) are detected by digestion with methyl-specific restriction enzymes, 
followed by amplification, labelling and hybridisation to a microarray as for a ChIP-on-chip 
assay [127]. DamID has been used to identify binding sites of proteins in different organisms 
and targeted the binding sites for sequence-specific TFs, DNA methyltransferase and 
chromatin-associated proteins using PCR-amplicon arrays or 60-mer oligonucleotide tiling 
arrays.  
 
DamID has some advantages compared to ChIP. For example, DamID is not dependent 
on the availability of high-quality antibodies. Moreover, there is no need to use crosslinking 
reagents, eliminating the risk of crosslinking artefacts. Third, DamID can be performed on 
about 106 cells, which is 10- to 100-fold less material than typically used in ChIP experiments 
[128]. However, DamID has also limitations. It requires an exogenous fusion protein, whereas 
ChIP can be performed with the endogenous protein; some proteins lose their genomic binding 
specificity when fused to Dam. DamID is also less suitable for the detection of rapid changes in 
protein binding (e.g., during the cell cycle), because the methylation patterns obtained in a 
typical DamID experiment represent the average of a time period of about 24 h or more. Last, 
DamID cannot be used to map post-translational modifications such as histone modifications; 
for such applications, ChIP-on-chip is more suitable. 
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1.2.8. Surface plasmon resonance (SPR) measurement 
Surface plasmon resonance measurement [129,130] is an optical technique that allows 
studying the interaction between an immobilised molecule and an analyte that is in solution. It 
relies on the change in the refractive index of solutions adjacent to a surface upon an increase 
in surface thickness, which is caused by analyte binding. In studies aimed at DNA-protein 
interactions, either the DNA-molecule is attached, for instance by means of biotinylation, or a 
protein is immobilised by tags, such as poly-histidine or glutathione-S-transferase. The system 
offers real-time recording of the association and dissociation of the analyte at the immobilised 
ligand, thus permitting rapid and accurate stoichiometric kinetic, affinity, and thermodynamic 
measurements [131]. With regard to quantitative measurements, this procedure is currently the 
gold standard for protein interaction analysis. 
 
1.2.9. Systematic evolution of ligands by exponential enrichment (SELEX) 
SELEX has been used to identify high-affinity nucleic acid ligands for a large number 
of proteins. It exploits the power of genetic selection and the advantages of in vitro 
biochemistry. The assay is done by selecting a subset of oligonucleotides from a complex 
mixture of nucleic acid sequences. This is achieved by incubation of the DNA with the 
investigated protein, separation of bound molecules from the unbound fraction, release and 
amplification. This process is repeated iteratively until the nucleic acid sequences that bind to 
the protein with high affinity are enriched significantly [132]. The SELEX method enabled in 
vitro selection of the optimal binding sites of several TFs [133], for example. A limitation is the 
fact that the system does not allow to define the exact in vivo selectivity of proteins but is 
aiming at the identification of the best binding DNA-targets. 
 
1.2.10. Yeast one-hybrid system 
The yeast one-hybrid system [134] is conceptually similarly designed to the yeast two-hybrid 
system that is used for the detection of protein-protein interactions. A DNA sequence of 
interest (the DNA bait) is cloned upstream of a reporter gene and integrated into the yeast 
genome by site-specific recombination. At the protein side, a hybrid protein is generated by 
fusion of the prey protein to a transcription activation domain. When the prey protein and the 
DNA bait physically interact with each other, the reporter gene expression is activated. By 
generating libraries of DNA-fragments and fusion proteins, complex analyses can be 
performed. With this system, 283 interactions between 72 C. elegans digestive tract gene 
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promoters and 117 proteins could be identified [135], for example. A similar system but based 
on bacteria rather than yeast has also been described [136]. 
 
1.2.11. Proximity ligation 
A technique that permits an analysis even at single-molecule level is proximity ligation 
[137]. It is a method for very sensitive solution-phase detection of interaction partners. While 
mostly useful for studying protein-protein interactions, also the DNA-binding of proteins can 
be investigated. To this end, three probe molecules are required; one is an antibody against the 
investigated protein, the second is the DNA recognition sequence in form of a double-stranded 
DNA. Both molecules have attached a single-stranded DNA-tag segment. The third molecule 
needed is an oligonucleotide that is complementary to the ends of both DNA-segments. The 
target protein binds to the DNA probe and is subsequently detected by the antibody. In 
consequence, the two DNA-segments attached to antibody and DNA-fragment will come in 
close proximity. Only then they can hybridise to the oligonucleotide, which acts as a connector 
(figure 13). In the resulting double-stranded sequence, the DNA-segments of antibody and 
recognition sequence can be joined by an enzymatic ligation. The resulting sequence can be 
specifically amplified and detected in real-time by PCR or rolling circle amplification [138]. 
 
While this technique is powerful in terms of specificity and sensitivity, it is very 
dependent on the availability of specific antibodies. Also, extensive preparative steps are 
required in order to perform the analysis. In principle, the approach permits a parallel 
investigation, as long as specific sequences are attached to each pair of probe molecules. Also, 
the method is less suited for the identification of new binding sites, since no connector 
molecule would be available for their detection. For in vivo studies of defined protein-DNA 
interactions at the level of single-molecule sensitivity, however, the method could become 
enormously useful for its sensitivity and specificity. 
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Figure 13.  Schematic presentation of a proximity ligation assay. Upon incubation of a DNA-
fragment, an appropriate protein and an antibody that binds the protein, a complex of the three 
molecules is formed. Both the DNA-fragment and the antibody are tagged with single-stranded 
DNA-segments. After addition of an oligonucleotide that is complementary to both ends of the 
tag sequences, the DNA molecules are joined by ligation and can then be amplified by PCR. 
 
 
1.2.12. Microarray-based assays 
For the achievement of high-throughput analysis, microarray technology was an 
obvious candidate. In consequence, studies have been performed that employed microarrays for 
the detection of DNA-protein interactions. Either DNA or protein microarrays were utilised to 
this end.  
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1.2.11.1.  DNA microarrays 
As already reported above, ChIP-on-chip and microarray-based DamID improved the 
throughput of the basic methods considerably and are currently still the most widely used array-
based methods for the identification of transcription factor binding sites. However, DNA-
microarrays can also be used for a direct analysis of DNA-protein interactions. Yet, since most 
sequence-specific DNA-binding proteins bind to double-stranded DNA, processes had to be 
developed to create double-stranded DNA-molecules on chip surfaces. DNA-microarrays used 
for other purposes are usually made of single-stranded DNA. 
 
In some studies, PCR-products were printed on microarrays [139]. As an alternative, 
and superior in terms of investigating the specificity of binding, analyses were performed on 
oligonucleotide arrays. Double-strand formation can be achieved by synthesising long 
oligonucleotides, which consist of self-complementary sequences, therefore forming hairpin 
structures. Alternatively, the second DNA-strand can be produced enzymatically by means of a 
sequence that is common to the 3’-end of all single-stranded oligonucleotides on the array. 
Upon addition of a complementary primer molecule and an appropriate polymerase, the 
initially single-stranded oligonucleotides are converted to DNA duplexes [140]. 
 
For monitoring protein binding, first the protein of interest is expressed. Frequently, an 
expression system has been used that adds an epitope tag. Such a tag has two functions: first, it 
is used to isolate the protein by affinity-purification and, second, it permits detection by means 
of an epitope-specific reporter, such as an antibody. Alternatively, directly labelled proteins can 
be used in the assay. The protein is incubated on the microarray and the signal intensities 
obtained at the various array features are measured. The method was applied successfully in 
several studies for an analysis of proteins that had been uncharacterised before [141,142].  
 
In terms of coverage, microarrays were used that contained PCR-products, which 
covered entire genomes [142,143]. Microarrays made of long PCR-products have the 
advantage that they cover much sequence space with relatively few microarray features. At the 
same time, however, they have the disadvantage that the probability of calling a binding event 
correctly is less for a single binding site, which is embedded in a long rather than a short 
sequence. Moreover, depending on the number and types of candidate binding sites within a 
single region, interaction may occur once or several times by one or several proteins at various 
degrees of affinity [144]. From the blend of information gained from such measurements, it 
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may well be impossible to extract how many interactions are involved, let alone any accurate 
information about strength and specificity. For such ends, arrays that consist of short synthetic 
double-stranded oligonucleotides exhibit superior performance [145,146]. While coverage of 
all binding sites in a genome is unlikely to be achieved with oligonucleotide arrays – and 
unnecessary because of the advent of sequencing techniques that are better suited for this 
purpose – arrays have been produced that are comprehensive with respect to the binding 
sequences, presenting all 10 bp sequences possible for example [147,148]. 
 
1.2.11.2. Protein microarrays 
While analyses on DNA-microarrays promise a rather comprehensive identification of 
the target sequences of a specific transcription factor or other DNA-binding protein, they are 
not able to identify the various proteins, which recognize a particular sequence of interest. This 
is made possible, however, by reversing the assay format. Studies on protein arrays that 
represented 282 potential yeast TFs [149], 802 Arabidopsis TFs [150], or 4191 non-redundant 
human DNA-binding proteins [100], for example, demonstrated the potential of this approach. 
The arrays were created using epitope-tagged proteins, mostly by fusion to glutathione-S-
transferase. Subsequent to purification by affinity chromatography, the proteins were attached 
to the chip surface and incubated with double-stranded oligonucleotides. Each oligomer was 
made of three or four repeats of the relevant sequence motif. In human, for example, a total of 
17,718 DNA-protein interactions between 460 DNA-motifs and 4,191 human proteins were 
identified [100]. Among them was a large number of interactions of TFs with DNA sequences, 
which had not been anticipated before. Also, the binding characteristics of TFs were identified 
this way. Recent developments toward the production of comprehensive protein arrays 
[151,152,153] should permit an extension of the format. However, the structural integrity of the 
proteins or at least of their DNA-binding domains is of critical importance for a successful 
application and is unlikely to be conserved on a microarray surface for all molecules. In 
addition, problems could occur with proteins that need to form multimers or complexes with 
other proteins in order to exhibit their binding activity.  
 
 
 
Materials and Methods 
62 
 
2. Material and methods 
 
2.1. Materials  
2.1.1. Equipment 
Name Manufacturer  
PCR-Maschine PTC200 
Photometer (UV/Vis) 
M J Research BioRad, Waltham, USA 
Ultrospec 2000, Pharmacia Biotech, Freiburg 
Germany 
pH-Meter MP 230, Mettler Toledo, Germany 
Mini-Protean®3 electrophoresis chamber and 
casting unit 
BioRad, Waltham, USA 
Photometer (UV/Vis) Ultrospec 2000, Pharmacia Biotech, Freiburg, Germany 
Hoefer TE 70 (Semi dry Wester-Blot) Amersham Bioscience, Piscataway, USA 
ND 1000, NanoDrop, Spectrophotometer NanoDrop, Wilmington, DE USA 
Oven  Haereus, Hanau, Germany 
Centrifuge  5810R, Eppendorf, Hamburg Germany 
Centrifuge 5415D, Eppendorf, Hamburg Germany 
ESI spotter Eurogebtec, Biorad, Munich, Germany 
MicroGrid II spotter Genomic Solution, Huntington, UK 
SMP3 pins TeleChem International, Sunnyvale, USA 
ScanArray 4000XL Perkin Elmer, Boston, MA, USA 
ScanArray 5000 Perkin Elmer, Boston, MA, USA 
 
 
2.1.2. Chemicals 
Name  Manufacturer  
Acrylamide/Bisacrylamide Roth, Karlsruhe, Germany 
Agar Roth, Karlsruhe, Germany 
Agarose Invitrogen, Carlsbad, USA 
Ammoniumpersulfate (APS) Roth, Karlsruhe, Germany 
Ampicillin (sodium salt) Genaxxon, Munich, Germany 
BSA (bovine serum albumin) Sigma-Aldrich, Schnelldorf Germany 
Chloramphenicol Genaxxon, Munich, Germany 
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Dithiothreitol (DTT) Invitrogen, Carlsbad, USA 
Ethanol, absolute Riedel de Haën Sigma, Seelze, Germany 
Ethidium bromide AppliChem, Darmstadt, Germany 
(EDTA) Sigma-Aldrich, St.Louis, USA 
Glycerol J.T.Baker, Deventer, Holland 
Hepes Roth, Karlsruhe, Germany 
Imidazole Roth, Karlsruhe Germany 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Roth, Karlsruhe, Germany 
Kanamycin Genaxxon, München, Germany 
Methanol VWR, Darmstadt, Germany 
Protein-Marker: Broad Range NEB, Frankfurt Germany 
Sodium dihydrogenphosphat (NaH2PO4 x 
H2O) 
Roth, Karlsruhe, Germany 
Sodium chloride Riedel de Haën Sigma, Seelze, Germany 
TEMED Roth, Karlsruhe, Germany 
Tetracyclin Genaxxon, München, Germany 
Triton X 100 Gerbu, Gaiberg, Germany 
Tris-base Sigma-Aldrich, St.Louis, USA 
Tris-HCl Sigma-Aldrich, St.Louis, USA 
Tryptone/Peptone Roth, Karlsruhe, Germany 
Tween 20 Sigma-Aldrich, St.Louis, USA 
Yeast extract Gerbu, Gaiberg, Germany 
 
 
2.1.3. Kits 
Name  Manufacturer  
Qiagen QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
Qiagen QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
Pierce HisPur cobalt spin columns Thermo Fisher Scientific, Waltham, USA 
Synthesis-Kit für Geniom 2x Sigma, Seelze, Germany 
 
 
2.1.4. Buffers and mediums 
Buffer  Composition  
Binding buffer 5X 0.1M Hepes pH 8.0, 0.25M KCl, 25mM DTT, 
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0.25mM EDTA, 5mM MgCl2, 25% v/v 
glycerol 
Ethidium bromide solution for staining  0,5 μg/ml Endkonzentration 
Laemmli buffer 30,1 g Tris Base, 144,2 g Glycine, 50 ml SDS 
(20%), ad 1 l dH2O 
LB-Agar LB-Medium + 1,5% (w/v) Agar 
LB-Medium (1 liter) 10 g Tryptone/Pepton, 5 g yeast extract, 10 g 
NaCl, pH 7.2 
PBS 10x (1 liter) 80 g NaCl, 2 g KCl, 26.8 g Na2HPO4, 2.4 
g KH2PO4, pH7.4 
Spotting buffer (buffer E) 20mM HEPES-KOH, 0.4mM EDTA, 1mM 
DTT, 100mM NaCl, 25% v/v glycerol, pH 8 
TBE 10x (1 liter) 108 g Tris, 55 g Boric acid, 40 ml 0,5 M 
Na2EDTA (pH8) 
TBS 10x (1 liter) 50 mM Tris, 150 mM NaCl mit HCl, pH 
7.5 
TBST 1X TBS/ 0,05% Tween20 
Transfer buffer 150 mM Glycine, 25 mM Tris-base, 20% 
Ethanol 
 
2.1.5. Labware 
Name  Manufacturer  
Falcon 15 ml and 50 ml Becton Dickinson, Heidelberg 
Polyfiltronics TM Uniplate, 384er, V-bottom Nunc GmbH & Co.KG 
Microtiter cover film Nunc GmbH & Co.KG 
Geniom - Biochip Sigma, Seelze, Germany 
Lazy-L-Spreaders Sigma-Aldrich, St.Louis, USA 
Disposable cuvettes  UVette, Eppendorf, Hamburg Germany 
Latex gloves  Latex, Blossom Mexpo, Hayward, USA 
Nitril gloves Nitril, Microflex, Wien, Österreich 
Parafilm PM 996, Pechiney Plastic packaging 
Sterile filter 500 ml Nalgene, Rochester, USA 
Cell culture Petri dishes 96x20mm stock 
Eppendorf reaction vessels Safe Lock Tubes 1,5ml und 2ml, Eppendorf, 
Materials and Methods 
65 
Hamburg Germany 
2.1.6. Enzymes, vectors, bacterial strains 
Name  Supplier  
LR clonase  Invitrogen, Karlsruhe, Germany 
BssHII NEB, Frankfurt, Germany 
pDEST17 Invitrogen, Karlsruhe, Germany 
BL21-AI One Shot Invitrogen, Karlsruhe, Germany 
Rosetta-Gami2 (DE3)  Novagen, Darmstadt, Germany 
 
 
2.1.7. Software and web pages 
Software   
GenePix Pro 6.0 Axon Instrument, Inc., Union City, USA 
Search of rare codons in nucleotide 
sequence 
http://molbiol.edu.ru/eng/scripts/01_11.html 
PROTEIN CALCULATOR v3.3  
Recombinant Protein Solubility Prediction 
http://www.scripps.edu/~cdputnam/protcalc.html 
http://www.biotech.ou.edu/ 
Protein molecular weight http://www.bioinformatics.org/sms/prot_mw.html 
TESS : Transcription Element Search 
System 
http://www.cbil.upenn.edu/cgi-bin/tess/tess 
 
 
2.2. Methodology 
Setting up TFs-chip  
The aim of this part was the establishment of protein microarray for studying DNA-protein 
interactions. Practically in the lab, getting specific signal resulted from DNA-protein 
interactions on the microarray surface was the goal in the lab. Therefore, we followed several 
steps to pursue our objective as the following: 
2.2.1. DNA-binding protein expression and purification. 
2.2.2. Protein spotting and immobilization on the proper surface chemistry keeping the 
protein functional. 
2.2.3. On-chip DNA-protein interactions. 
2.2.4. Verifying Transfac database consensus sequences using DNA-microarray. 
2.2.5. Applying oligos, PCR products of promoter regions, and genomic DNA to TFs-
chip. 
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2.2.1. DNA-binding protein expression and purification 
2.2.1.1. Protein expression 
In the present study, in total fifty proteins were expressed and purified. To express the 
proteins and to purify them, several troubleshooting were faced which is covered in details the 
discussion section. The Open Reading Frames (ORFs) of the DNA-binding proteins were 
obtained from Prof. Jussi Taipale, Helsinki, Finland. Therefore, the protein expression was 
started from shuttling the ORF into the gateway destination expression vector (pDEST-17) 
using the LR clonase (Invitrogen, Karlsruhe, Germany). The LR recombination reaction was 
performed overnight at 25°C in the Thermal cycler with heated lid. Then, DH5α library 
efficiency was transformed according the manufacturer’s protocol. In the next day, the colonies 
were picked up in 2ml LB medium (with 100µg Ampecillin/ml) and incubated overnight at 
37°C with shaking at 240rpm and the plasmid was isolated using Qiagen miniprep kit (Qiagen, 
Hilden, Germany). Afterward, Rosetta-Gami2 (DE3) (Novagen, Darmstadt, Germany) was 
transformed according the manufacturer’s recommendations. In 10ml LB medium (with 100µg 
ampecillin/ml, 12.5µg/ml tetracycline, and 36µg/ml chloramphenicol), the colonies were 
picked up and incubated overnight at 37°C with shaking at 240rpm. In order to induce the 
protein expression, the bacteria were diluted 1:5 times with LB medium (100µg ampecillin/ml, 
12.5µg/ml tetracycline, and 36µg/ml chloramphenicol) in a flask. The bacteria were incubated 
at 37°C with shaking at 240rpm till reaching OD 600 of 0.6. At OD600 of 0.6, protein 
expression was induced by adding 0.1mM IPTG and incubated overnight at 37°C with shaking 
at 240 rpm. Finally, the bacterial pellets were collected by centrifugation at 4000 rpm at 4°C 
and stored at –20°C for further investigations and purification. 
 
2.2.1.2. Protein detection and purification 
The expressed proteins were detected by Western blotting using anti-6His antibody-
peroxidase (Roche Diagnostics, Mannheim, Germany). Protein samples were resolved on SDS-
polyacrylamide gel and electrophoretically transferred using semidry blotting blot to 
nitrocellulose membranes (Amersham Pharmacia Biotech, Buckinghamshire, UK). After 
blocking, membranes were incubated with anti-6His antibody-peroxidase for one hour at room 
temperature. Afterward, bands were detected by chemiluminescence using the ECL Western 
Blotting Detection System (Amersham Pharmacia Biotech, Buckinghamshire, UK).   
 
Materials and Methods 
67 
In the case of successful protein expression, the recombinant proteins were purified 
using Pierce HisPur cobalt spin columns (Thermo Fisher Scientific, Waltham, USA) using the 
denaturing protocol according to the manufacture instructions. To reach the optimum 
conditions, several protocols were used as detailed later in the discussion section. 
 
2.2.2. Protein spotting and immobilization 
After testing many conditions for the surface, spotting buffer, and immobilization 
temperatures, the proteins were spotted at a concentration (20-100ng) in Buffer E (20mM 
HEPES-KOH, 0.4mM EDTA, 1mM DTT, 100mM NaCl, 25% v/v glycerol, pH 8) on epoxy-
coated glass slides (Schott-Nexterion, Jena, Germany) using a MicroGrid II (Genomic 
Solutions, Huntington, UK) equipped with SMP3 pins (TeleChem International, Sunnyvale, 
USA). After printing the slides, the proteins were immobilized at 37°C overnight. 
 
2.2.3. On-chip DNA-protein interactions 
Prior to hybridization, the slides were washed in 1X binding buffer for 30 min. The 
Hybridization was carried out by incubating the labeled DNA (oligos or PCR product from 
promoter sequences) using LifterSlips (Erie Scientific, Portsmouth, USA) for one hour at room 
temperature. Subsequently, the slides were washed in 1X binding buffer for 10 min followed by 
another 10 min in TBST and briefly with distilled water. Then, the slides were dried with N2 
and the signals were detected immediately.  
The DNA-protein interaction signals were detected by confocal four-color laser 
scanners (ScanArray 4000XL and ScanArray 5000, Perkin Elmer, Boston, MA, USA). The 
quantification of the signal intensities was done with GenePix Pro 6.0 analysis software (Axon 
Instruments, Inc., Union City, USA). 
 
Furthermore, for more confirmation, to avoid the doubt that the signals obtained by the 
microarray could be referred to fluorechrome-protein interaction and not DNA-protein 
interaction, the DNA was digested by DNase I prior to the microarray incubation.  
 
2.2.4. Electrophoretic Mobility Shift Assay (EMSA) 
The assessment of the DNA-protein interactions was done by comparing the results of 
microarray interaction signals with the results using EMSA. In EMSA, the biotinylated DNA 
was incubated with 50ng of the target proteins in 1X binding buffer for 30 min at room 
temperature. Then the bands were resolved on 10% non-denaturing polyacrylamide gel. The 
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bands were blotted on Nylon membrane and immobilized by UV-crosslinking. The membrane 
was incubated subsequently with streptavidin-POD for 30 min at room temperature. Finally, the 
bands were detected by chemiluminescence using the ECL Western Blotting Detection System 
(Amersham Pharmacia Biotech, Buckinghamshire, UK).   
 
2.2.6. Verifying Transfac database consensus sequences using DNA-microarray 
Several consensus sequences could be obtained from Transfac database with several 
qualities that based on the method of the DNA-binding protein verification. Therefore, we have 
applied a DNA array with sequences derived from the Transfac consensus sequence to 
investigate the protein preference and subsequently the sequences could be useful for TF-chip 
application.  
 
  The DNA-microarray was designed with Microsoft Excel on Linux program prepared 
Mutscan and the Geniom software, Febit. All possible permutations of one or two nucleotides 
were generated from the Transfac consensus sequence with the program Mutscan. The 
expansion on 125,000 spots per array enabled the investigation of all possible 9 mer binding 
sequence. The necessary consensus sequences and protein information were related of 
following source: 
 http://www.biobase.de/pages/index.php?id=transfacdatabases 
 
The oligonucleotides synthesis was executed in the Geniom device (Febit, Heidelberg, 
Germany) through chemical synthesis using commercially available synthesis kits. Each 
spotted sequence was complementary. Therefore, they could form the double-stranded DNA 
through hairpin formation. After the DNA synthesis, all of the washing steps and protein 
reaction were carried out in an external unit. Firstly, the chip was blocked for an hour with 2% 
BSA in 1x PBS. Then, the TF-protein in 1X binding buffer with 2% BSA was incubated 1hour. 
Subsequently, the 8 arrays of the chips were washed with 1X binding buffer with 2% BSA. The 
further incubations were performed in the Geniom 2X system as the following: 
 
• Protein detection by the anti-His antibody: 10 ml, 1X binding buffer + 10 µl 
biotinylated anti-His antibody. 
• SAPE-solution (streptavidin-phycoerythrin): 9 ml 1x Binding buffer + 44 µl SAPE + 
2% w/v BSA 
• Wasch-solution: 80 ml 1x Binding buffer + 2% w/v BSA 
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 The Phycoerythrin dye is detected by means of an integrated Cy3-Filtersets. Typical 
exposure times lay in the area of 1000-5000 ms. The data (in the form of signal intensity) were 
analyzed using Microsoft Excel and Sigmaplot from Systat software.  
 
2.2.7. Applying oligos, PCR products of promoter regions, and genomic DNA to TFs-chip 
Using accordant consensus sequences from the literature, DNA-chip results of ETS1 
and SPI1, and galectin-4 promoter study, we pursued to validate and optimize the TF-chip.  
 
 
 
Protein name DNA response sequence  
KLF8 caccctagagCCACACCCTggtaag 
NFKB1 (1) ctgtAGTTGAGGGGACTTTCCCAGGCactg 
NFKB1 (2) agccggtagggaagcccccaggaagcgcctg 
NFKB1 (3) ggcgcttcctgggggcttccctaccggctc 
ETS1 (DNA 
array results) 
AGGGGAAGGAGGGGAAGGAGGGGAAGGAGGGGAAGG 
 
SPI1 (DNA 
array results) 
GGAGAAAGTGGAGAAAGTGGAGAAAGTGGAGAAAGT 
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3. Results 
 
3.1. Protein expression and purification 
In the present study, 50 proteins were successfully expressed and purified with end 
concentrations ranging from 0.02 mg/ml to 0.2 mg/ml. The detection of the expression was 
carried out using Western blotting against the 6his-tag. The successfully expressed proteins 
were then purified and the quality was checked using SDS-PAGE followed by comassie blue 
staining and Agilent 2100 Bioanalyzer (figure 14 and 15).  
 
 
 
Figure 14. Nine different purified transcription factors proteins detected by Agilent 2100 
Bioanalyzer. 
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Figure 15.  Western blotting of recombinant unpurified ETS1 and KLF5.  In the left panel (a), 
the bacterial lysate was incubated with anti-his antibody, which shows the band of the target 
recombinant protein and also showing some his-rich proteins from the bacterial source. In the 
right panel (b), the bacterial pellets were incubated with the specific antibodies (anti-ETS1 and 
anti KLF5). As it is clear, the bacterial his-rich proteins are not detected, since the specific 
antibodies were used. In the case of ETS1, the main protein band is shown with extra bands 
that could be either degraded ETS1 protein or truncated protein. 
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At the beginning of this project, the protein expression experiment was started with two 
proteins (JUN and NFKB1) in BL21 bacteria strain. Figure 16 shows the MALDI-TOF analysis 
of the JUN protein which was obtained after protein expression and purification and as it is 
clear in the figure, truncated JUN protein (28.9 KD instead of 35.7 KD). In case of NFKB1, no 
protein was obtained. 
 
 
Figure 16. MALDI-TOF analysis of the recombinant JUN protein that was expressed in BL21 
bacteria strain: The figure shows a high peak intensity of 28.9 KD that represents the truncated 
protein.  
 
 
One of the factors that could influence protein expression is rare codons. Therefore, the 
in case NFKB1 and JUN, the presence of rare codons was investigated using a rare codons 
calculator (http://www.bioline.com/calculator/01_11.html). Subsequently, several rare codons 
were found in JUN and NFKB1. In the case of JUN, the rare codons were located the end of the 
ORF (figure 17a), which could explain the abundance of 28.9KD protein product. On the other 
hand, NFKB1 ORF sequence was overloaded with rare codons (figure 17b) and subsequently 
NFKB1 was not expressed at all. Therefore, using Rosetta-gami 2 (DE3) that contain tRNA for 
rare codons, the full-length proteins were obtained.  
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Figure 17. The rare codons distribution among JUN and NFKB1 ORFs: Using the rare codons 
calculator (http://www.bioline.com/calculator/01_11.html), the rare codons were clustered at 
the end of JUN ORF sequence(a). While in the NFKB1 case (b), the rare codons were 
distributed along the whole sequence. R is referred to rare codon. 
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As in details later in the discussion section, using Ni-NTA Agarose for His-tagged 
protein purification, on column depending on the gravity sedimentation, bacterial proteins 
contamination was obtained. Therefore, we switched to cobalt spin column and hence the 
protein purity was increased. 
 
3.2. Protein spotting and immobilization 
Six TF-proteins were immobilized on several types of coated surfaces (Ni, 2D-Epoxy, 
3D- Epoxy (glass and COC slides), and 3D- aldehyde (glass and COC slides)) at room 
temperature and 60°C. Subsequently, for the quality control, the immobilized proteins were 
stained using Sypro-Ruby. In order to increase the immobilized protein quantity and eliminate 
the high background obtained using the 3D coated slides as shown in figure 18, 2D-Epoxy 
coated glass surface was selected to pursue the TF-chip further optimization.  
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Figure 18. Optimization of the surface chemistry to immobilize TFs proteins. Six different 
proteins were immobilized on different types of coated slides and at two different temperature. 
Then, in order to detect the immobilization quality, the slides was stained with sypro ruby and 
scanned. 
 
 
Results 
76 
 
In parallel, several spotting buffer have been investigated (PBS, adding Tween 20, 
verifying the glycerol concentration). Figure 19 shows the results of using five different 
spotting buffers. A protein solubility problem was probably obtained with PBS and 
subsequently the proteins were washed away and therefore are not shown on the array. Adding 
detergent (tween 20) was enhanced the protein solubility but in parallel decreased the surface 
tension of the spots. Using another buffer caused donuts-shape spots. On the other hand, adding 
glycerol to the spotting buffer increased the surface tension of the spots and consequently 
adjusted the shape of the spot. However, 40% v/v glycerol caused a problem while spotting 
process due to sticking to the pins (detected by spotting water that showed signals from 
contamination).  
 
 
Figure 19. The results of testing different spotting buffer: 150ng NFKB1 protein dissolved in 
five different buffers and hybridized by Texas Red labeled NFKB1 consensus sequence. Using 
mere PBS caused evaporation of the spotting buffer and subsequently protein aggregation and 
therefore proteins were washed away afterward. Adding glycerol increased the surface tension 
and therefore enhanced the spot shape. Including Tween20 in the spotting buffer increased the 
protein solubility, but decreased the surface tension of the protein and then increased the spot 
size. Sodium salt rich buffer greatly decreased the surface tension and caused donuts-shape 
spots. 
 
 
In the next step, when many proteins were applied and after storing the recombinant 
proteins more than two months, the spotting was not working properly which could be referred 
to protein aggregation. Several suggestions were considered like adding detergent or imidazole 
to the spotted proteins. In order to investigate whether adding detergent will increase the 
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protein solubility or not, two detergents were applied to the proteins (10% SDS and 4M urea).  
Comparable to the proteins without detergent, SDS and urea were increased the protein 
solubility in different grade (figure 20). While SDS was enhancing the solubility, it was also 
impairing the surface tension of the spots. As a result from this experiment, urea was selected 
for further investigation to increase the protein solubility, but at the same time to check the 
functionality of the proteins under such denaturing conditions. For that purpose, two different 
concentrations of NFKB1 protein was calibrated against three different concentrations of urea 
(figure 21). After comparing protein concentration, urea molarity, and the signals intensity, we 
decided to use 1M urea that increased the protein solubility and didn’t interfere with the protein 
function. 
 
 
 
 
Figure 20. Adding denaturant to the spotted protein: 150ng NFKB1 protein dissolved using 
20% glycerol/PBS with two different denaturing agents (10% SDS, 4M urea) and hybridized by 
Texas Red labelled NFKB1 consensus sequence. Moreover, the different solutions were spotted 
alone as negative controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
78 
 
 
Figure 21. The calibration of urea concentration: a. NFKB1 protein was spotted in two 
different concentrations (350 ng and 175 ng) and three different urea concentrations and b. is 
the corresponding signal intensity.  
 
 
Adding imidazole to his-tagged proteins was another solution to avoid their 
aggregation. Therefore, 120mM imidazole was added to the TF-proteins and spotted using the 
previous mentioned spotting and immobilization conditions. In addition to TF-proteins, 
spotting buffer and BSA were spotted as negative controls and hybridised by a labeled PCR 
product of IL-8 promoter (since IL-8 promoter has NFKB1 binding site). The results of this 
experiment showed increased solubility of the proteins, but on the other hand a strong signal 
was obtained from the spotting buffer (the negative control) as shown in figure 22. 
 
 
 
 
 
a. 
b. 
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Figure 22. Adding 120mM Imidazole to the spotting buffer showed increasing in the 
recombinant protein solubility. However, on the other hand, in this histogram, as indicated with 
the arrowheads, the spotting buffer with imidazole gave strong signals while scanning. In this 
experiment, the TFs-chip was hybridized with a PCR product of IL-8 promoter. 
 
 
Another point to control the solubility and the DNA-protein interactions on chip was the 
spotted protein concentration. In that regards, different NFKB1 protein concentrations (300 ng, 
200 ng, 100 ng, and 50 ng) were spotted and hybridized by labeled NFKB1 binding-sequence. 
As shown in figure 23, the less the concentration (100 ng or 50 ng) the better the obtained 
signals. Therefore, 50-100 ng of the TF-protein was used in the spotting process. 
 
Figure 23. Optimizing the spotted protein concentration: NFKB1 protein was spotted in four 
different concentrations and hybridized with the labeled NFKB1 response element sequence (a) 
and the signal intensities were calculated and compared as shown in the histogram (b).  
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From the previous results, we decided to use the following conditions: 1) spotting on 
2D-epoxy surface, 2) immobilizing at 60°C for one hour, 3) adding 1M urea to the spotting 
buffer, and 4) using 50-100 ng of the recombinant protein. However, using labeled genomic 
DNA as positive control, applying the 50 proteins to the chip, the conditions were not 
compatible with every protein for the DNA-protein interaction. Thus, playing with all of 
alternative (spotting buffer, adding detergent, and immobilization temperature), the conditions 
were changed again to suit all of the proteins to: 1) spotting on 2D-Epoxy surface, 2) 
immobilization at 37°C overnight, 3) dissolving the proteins in buffer E which contains DTT as 
a detergent, and 4) using 50-100 ng of the TF-proteins. 
 
3.3. On-chip DNA-protein interaction  
After getting DNA-protein interaction on the TF-chip, the determination of the reaction 
specificity was next step to execute. Therefore, two experiments were done: 1) investigating 
whether it is DNA-protein interaction or Fluorochrome-protein interaction, and 2) validation of 
the microarray results using EMSA. 
 
3.3.1. DNA-protein interaction and not Fluorochrome-protein interaction 
To investigate whether it is DNA-protein interaction or Fluorochrome-protein 
interaction, the PCR product of IL-8 promoter was digested using DNaseI prior to the 
hybridization. Since it is known from the literature that IL-8 promoter binds to NFKB1, the 
NFKB1 protein was spotted on two slides and subsequently two chips were hybridized by 
digested and undigested PCR product. Indicating that it is DNA-protein interaction and not 
Fluorochrome-protein interaction, the digested PCR product did not show any signal 
comparable to the strong signals obtained by the undigested PCR product (figure 24). 
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Figure 24. NFKB1 protein was spotted on two chips and hybridized using: (a) 206bp from IL-
8 promoter and (b) 5 min DNaseI digested PCR product of IL-8. 
 
 
 
3.3.2. TFs-array validation by EMSA 
In order to verify the TFs-chip results, in parallel to the protein array hybridization with 
the target DNA sequence, EMSA was done. As shown in figure 25, upon incubation of TFs-
array with 30-mer double-stranded oligonucleotides from the NFKB1 promoter sequence and 
the corresponding parallel EMSA experiment results, the two results (TFs-chip and EMSA) 
were concordant in terms of binding strength.  
 
 
 
 
 
 
a b 
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Figure 25. Comparison of results from a protein array measurement and a related EMSA 
experiment. Transcription factors were used to produce a protein microarray. Panel (a) shows 
signal intensities obtained upon incubation with a 30-mer double-stranded oligonucleotide, 
whose sequence had been selected from the promoter region of NFKB1. Results at four 
transcription factors and a BSA negative control are shown, clearly illustrating the fact that 
particular sequences may be shared between transcription factors, especially if members of a 
family. In panel (b), the corresponding results of an EMSA experiment are presented. In the 
lane labelled with DNA, no protein had been added. The extent of the band shifts corresponds 
with the array data. 
 
 
3.4. Verifying Transfac database consensus sequences using DNA-
microarray 
One of the important points that was considered in this study is to select the DNA 
response element sequence, in order to investigate the specificity of TF-array. Therefore, we 
used Transfac database to retrieve the consensus sequences from the previous studies. Several 
consensus sequences were annotated with different quality ranging from 1 to 6. In this study, 
quality 2 was selected, which was in previous studies validated using recombinant proteins. In 
this experiment, a DNA-array was synthesized as mentioned before in the method section and 
SPI1 and ETS1 proteins were applied. After getting the results in the form of signal intensities, 
the highest signals were selected (table 8 and 9) and analysed to get the consensus sequences 
(figure 26).  
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Figure 26. DNA-microarray results for ETS1 and SPI1 transcriptional proteins: the figure 
shows the consensus sequences of the two proteins that were obtained after the selection of the 
best signal intensities. 
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sequence Signal Mean 
GGAGGAAGT 15473 
AGGGGAAGT 15499 
AGAGGAAGC 15066 
AGAGGGAGT 15140 
CGAGGGAGT 15075 
CGAGGAATT 16684 
GGGGGAAGT 16400 
GGAGAAAGT 16270 
AGGAGAAGT 15118 
AGGCGAAGT 15186 
AGGGTAAGT 15610 
AGGGAAAGT 15359 
AGGGCAAGT 15448 
AGGGGCAGT 16675 
AGGGGTAGT 15757 
AGGGGACGT 15865 
AGGGGATGT 15490 
AGGGGAAAT 15380 
AGGGGAAGA 17425 
AGGGGAAGG 18433 
AGTCGAAGT 15227 
AGTGTAAGT 15194 
AGTGCAAGT 15104 
AGTGGGAGT 15260 
AGTGGTAGT 15366 
CGCGGAAGT 15123 
CGAGTAAGT 15174 
GGGGGAAGT 17157 
GGAGAAAGT 16730 
GGAGGAAGG 15095 
AGGGGAAGA 16181 
AGGGGAAGG 17700 
GGGGGAAGT 15390 
GGAGAAAGT 15355 
AGGGGAAGG 15297 
AGACGACGT 15054 
CGGGGAAGT 18309 
AGGGGAAGG 16135 
AGAGTTAGT 26615 
AGAGTACGT 25800 
ATAGGACGT 19228 
ATAGGAGGT 17270 
AGGGGAAGG 15275 
AGGGGAAGA 17353 
AGGGGAAGG 15162 
AGGGGAAGA 17972 
AGGGGAAGG 20186 
AGGGGAAGG 15158 
 
Table 8. ETS1 response element 
obtained from the verification of 
Transfac database consensus 
sequence.  The retrieved Transfac 
sequence subjected to in silico 
permutation. Then, the permutated 
sequences were synthesized using 
Geniom software. Subsequently, the 
DNA-chip was hybridized by ETS1 
protein and the DNA-protein 
interaction was detected by anti-his 
tag antibody. The highest 50 signals 
were then selected and their 
sequences were analyzed to get a 
common consensus sequence for 
ETS1 
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Sequence  Signal Mean 
AGGGGAAGG 20630 
GGAGAAAGT 20393 
TGAGGGAGT 20516 
TGAGGTAGT 20794 
AGGGGAACT 20344 
AGGGGAAGC 26756 
AGGGGAAGG 20441 
GGAGAAAGT 20866 
AGGGGAAGG 21353 
AGAGGAAGG 21544 
CTAGGAAGT 28175 
AGGGGAAGG 20857 
AGACGAAGA 25092 
AGACGAAGC 32457 
AGACGAAGG 25013 
AGGGGAAGG 22115 
AGGGGAAGC 20153 
AGGGGAAGG 22939 
AGGGGAAGG 20420 
AGAGGAGGG 20046 
AGGGGAAGA 24787 
GGAGTAAGT 20158 
AGGGGAAGG 20838 
AAAGGAAGA 21100 
AAAGGAAGC 21840 
AAAGGAAGG 22411 
ACCGGAAGT 20279 
AGGGGGAGT 27548 
AGGGGTAGT 29007 
AGGGGACGT 28166 
AGGGGAAGG 20087 
AGAGCAAGC 22913 
AGAGCAAGG 22645 
AGAGGAATG 20713 
AGAGGAACC 22800 
AGAGGTAGT 22463 
AGAGGACGT 22739 
CGAGTAAGT 28362 
GGAGAAAGT 20138 
AGGGGGAGT 20378 
AGGGGAAGA 25316 
AGGGGAAGG 27922 
ATAGGAAGC 38265 
AGACGAAGC 20660 
AGAGTCAGT 20795 
AGAGTATGT 21617 
AGAGTAATT 21398 
AGAGTAAAT 21434 
AGAGAGAGT 22113,39062 
Table 9. SPI1 response element 
obtained from the verification of 
Transfac database consensus 
sequence.  The retrieved Transfac 
sequence subjected to in silico 
permutation. Then, the permutated 
sequences were synthesized using 
Geniom software. Subsequently, the 
DNA-chip was hybridized by SPI1 
protein and the DNA-protein 
interaction was detected by anti-his 
tag antibody. The highest 50 signals 
were then selected and their 
sequences were analyzed to get a 
common consensus sequence for 
SPI1. 
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3.5. Applying oligos and PCR product of promoter region 
 
3.5.1. Oligos from Transfac database and DNA-array results 
Incubating the labeled sequences that were obtained from Transfac didn’t work 
specifically with the target transcription factor protein. For example, the consensus binding 
sequence that was obtained for KLF8 protein was applied to TFs-chip. The results, as shown in 
figure 27, showed weak binding to KLF8. On the other hand, the sequence bound strongly to 
several other proteins like LEF1, ZNF140, and KLF5. 
 
 
Figure 27.  Applying Transfac consensus sequence of KLF8 protein on TF-chip: the KLF8 
protein showed a binding signal with the obtained Transfac sequence as defined by the red 
rectangle. However, he sequence bound strongly to several other proteins like LEF1, ZNF140, 
and KLF5. 
 
 
 
 
 
The next clue to verify the specificity of our TF-chip is utilizing the resulted consensus 
sequences of the DNA array for ETS1 and SPI1. Therefore, we used the obtained sequences as 
one unit of the binding sequence or as a four repeats of the binding motif as in the previous 
publication [100,149,150]. Using the single unit of the consensus sequence to hybridize the TF-
chip, which is composed of 9mers, didn’t show any signal. Using the four repeats of the 
binding motif sequence, the sequences bound to ETS1 and SPI1. However, the results showed 
even stronger binding to other proteins. Interestingly, since the obtained sequences from the 
results of DNA-microarray of ETS1 and SPI1 were different in one nucleotide, the resulted 
binding signals were more or less the same as shown in figure 28.   
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Figure 28. Upon the incubation of TF-chip with the consensus binding sequences of ETS1 and 
SPI1 proteins obtained from the DNA-array results in the form of four repeats, the sequences 
showed binding with ETS1 and SPI1 and some other proteins as well. The two sequences 
applied which are different in single nucleotide showed the same binding pattern with minute 
differences in the signal intensities.  
 
  
 
3.5.2. PCR products from promoter sequences 
From the first part of the thesis, utilizing the results of SNPs in LGALS4 promoter and 
their effects on the protein binding, the labeled PCR products of the promoter region with two 
SNPs in different genotypes were co-incubated on TFs-chip. Interestingly, the result of TFs-
chip was concordant with pull down – mass spectrometry results of galectin-4 promoter. In 
details, for example, P53 was detected as one hit in the mass spectrometry results in the 
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proteins that are binding to the wild type but not the mutant. In TFs-chip results as shown in 
figure 29, the P53 protein bound with signal intensity twice as the mutant type. The same result 
was encountered with RBBP7 that bound to wild but not the mutant type LGALS4 promoter in 
both pull down-mass spectrometry and TFs-chip experiments results. ENO1, FUBP1, and FUS 
were defined to bind both genotype sequences and that was the same on chip results.  
 
 
 
Figure 29. LGALS4 promoter with different SNPs on TFs-chip: a) scheme represents the 
outline of the experiment. The PCR product of the LGALS4 promoter was amplified with 
different SNPs. Each genotype was labeled with different fluorescent. Then, both PCR products 
were co-incubated on chip. B) The signal intensities results of both wild- and mutant- types. As 
indicated with arrowheads, both genotypes were shown to bind with ENO1, P53, RBBP7, FUS, 
and FUBP1 that was confirmed before with pull down – mass spectrometry experiments. 
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4. Discussion  
 
4.1. Protein expression, purification, and storage troubleshooting 
It was crucial for the present study to express pure, sufficient amount of, many, and 
functional proteins. Starting from the gateway cloning to protein purification, several 
troubleshooting were faced and subsequently the conditions were modified to get the target 
proteins in the desired form. In this section, the technical problems are discussed sequentially 
as faced during the experiment. 
 
4.1.1. Truncated protein expression  
At the beginning of protein expression experiment, we either did not get the proteins or 
truncated proteins were obtained. To overcome this problem, we prolonged the induction time 
in order to allow the full-length protein translation from four hours to overnight incubation. 
After time extension, still, there were some truncated proteins. Back to the fact that rare codons 
and rare codon clusters are capable of causing qualitative and quantitative expression problems 
in E. coli or other organisms [154,155]. These problems mainly occur on translation level rather 
than on transcription level. The main translational problems caused by rare codons or rare 
codon clusters include (a) that rare codons reduce the translation rate of the target gene, (b) low 
or undetectable amount of the expressed target protein, (c) misincorporation of amino acids into 
the target protein, (d) truncated or amino acids-deleted peptides or proteins are synthesized, and 
(e) frame-shifted peptides or proteins are synthesized [154,155]. Rosetta-gami 2  host strains 
combine the advantages of Rosetta 2 and Origami 2 strains to alleviate codon bias and enhance 
disulfide bond formation in the cytoplasm when heterologous proteins are expressed in E. coli. 
These trxB/gor mutants are compatible with kanamycin-resistant vectors, and carry the 
chloramphenicol-resistant pRARE2 plasmid, which supplies seven rare tRNAs. In Rosetta-
gami 2(DE3) pLacI, the rare tRNA genes are present on the same plasmid that carries the lac 
repressor gene. DE3 indicates that the host is a lysogen of λDE3, and therefore carries a 
chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. 
Such strains are suitable for production of protein from target genes cloned in pET vectors by 
induction with IPTG. Accordingly, we switched from BL21 competent cells to Rosetta-Gami2 
(DE3). As result of changing the bacterial strain, we started to get the first protein (NFKB1) 
that was not expressed at all BL21 strain. 
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4.1.2. Inclusion body and protein solubility 
In the bacterial cells, recombinant proteins usually fail to fold properly and accumulate 
as refractive, insoluble particles called inclusion bodies. In the previous studies, higher yields 
of soluble proteins have been pursued either by reducing the culture temperature, engineering 
the protein sequence, adding fusion partners or coproducing selected chaperones [156]. Under 
native conditions, we got a problem in purification. So, it was either no protein yield or less 
amount of protein comparable to the detected amount in the Western blotting. Therefore, we 
tried to minimize the induction temperature and time. Also, we changed the imidazole 
concentration in order to elute more amount of the His-tagged protein. None of those 
modifications enhanced the purified protein yield significantly. Under denaturating conditions 
the His tag is completely exposed, it will facilitate the binding to metal ions columns[157]. 
Thus, we switched to the denaturing conditions for dissolving the inclusion bodies, followed by 
protein refolding after the purification. 
 
4.1.3. Bacterial proteins contamination 
Technically, we faced bacterial proteins contamination. Regarding the 6His-tagged 
proteins, from the previous studies, it is recommended to optimise the imidazole concentration 
for the washing in order to minimize the contaminant proteins concentration or to increase the 
washing steps to get rid from the undesired bacterial proteins [157]. However, in our 
experiment, neither changing the imidazole concentration, nor the increasing of the washing 
steps enhances the situation.  It was applicable for decreasing the bacterial proteins 
concentration. But, on the other side, that decreased the concentration of the recombinant 
protein as well in the same proportion. Nevertheless, changing the purification method was 
helpful to overcome this troubleshoot. So, changing from the Ni-column that depends on the 
gravity to spin column successfully reduced the amount of bacterial proteins. From these 
results, we have suggested that with spin column, all of the solutions surrounding the metal ion 
and the recombinant protein are disposed completely during the centrifugation between each 
washing step. Consequently, it reduces the chance of bacterial protein contamination from the 
incomplete disposed solution. On the other hand, using column that depends on the gravity to 
get rid from the solution of each step, it is technically hard to get rid from the complete solution 
on the metal beads. Interestingly, also, switching from BL21 strain to Rosetta-Gami2 (DE3) 
strain reduced the amount bacterial protein contamination. That could be referred to the His-
rich protein amount in the different strain. Also, enhancing the amount of the 6 His-tagged will 
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increase the desired protein binding to the metal beads and subsequently will decrease the 
competition of bacterial proteins on the metal beads. 
 
4.1.4. Storage 
At the beginning of our experiment, after getting the recombinant proteins, we stored 
the proteins in PBS/20%glycerol at –20°C. After nearly two months, the proteins started to 
aggregate. From the literature, it was found that the histidine residues are implicated in 
triggering recombinant protein aggregation. At a physiological pH, histidine residues can form 
salt bridges with negatively charged amino acids and thereby mediating protein aggregation 
[158]. In a previous study, it was found that adding imidazole to the 6His-tagged recombinant 
proteins enhanced their solubility and stability [159]. Regarding the imidazole effect on 6His-
tagged proteins solubility, our result was concordant with the previous observations. So, adding 
imidazole to the storing buffer prevent protein aggregation. Unfortunately, on the other hand, 
the buffer was not consistent with the microarray downstream application. In other words, with 
adding imidazole to the protein buffer, we got unspecific fluorescent signal from the negative 
control, which was the buffer alone. From this point, we decided to store the protein in the 
elution buffer/8M urea at 4°C. Then, the proteins were desalted in the proper working buffer. 
 
4.2. Protein spotting and immobilization 
In order to carry out DNA-protein interaction on-chip, several factors had to be 
optimised. Therefore, we went through several setting up steps from optimising the surface 
chemistry, spotting buffer, and protein immobilization, till optimising DNA-protein interaction 
on-chip. 
 
4.2.1. Surface chemistry and protein immobilization 
Selection of the proper surface chemistry is one of the crucial steps to optimize 
microarray in general. Since surface chemistry is the interface between the immobilized 
molecules and the solid surface, it could affect the molecules functionality, spots morphology, 
background, hybridization, and subsequently the on-chip interactions [160,161]. In case of 
protein array, it is much more laborious to optimize a surface chemistry, since the proteins are 
more complicated and different molecules than nucleic acid. Proteins are easily losing their 
structure and biochemical activity due to denaturation, dehydration, or oxidation [162]. In 
principle, protein immobilization could be done using two strategies; 1) randomly oriented 
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proteins by means of noncovalent or covalent attachment, and 2) uniformly oriented proteins 
[163]. 
 
 In this study many surfaces were investigated to get the optimal conditions for spots 
morphology, proper protein immobilization on the surface, and less background noise. Thus, 
the immobilization was carried out using the mean of covalent random immobilization 
(aldehyde and epoxy surfaces in the forms of 2D and 3D chemistry) and also uniformly 
oriented proteins immobilization strategy was also investigated (Ni-coated slides). As shown in 
the results, using the 3D epoxy or aldehyde surfaces showed an increase of the immobilized 
protein. However, it caused a proportional increase of the background noise. On the other hand, 
using the Ni-coated slides, which is specific to immobilize his-tagged proteins, didn’t show 
proper amount of the immobilized proteins. Practically, the tertiary structure of the his-tagged 
proteins in solution could hide the 6His. Therefore, the improper immobilization of his-tagged 
proteins on Ni-coated slides in our experiment results might refer to the inadequate exposure of 
the his-tag to the Ni-surface. In terms of background noise and immobilized protein amount, 
the 2D-epoxy surface was the optimum surface used in our experiment to immobilize TF 
proteins. 
 
Another important factor that was considered in our experiment is the immobilization 
temperature. Two temperatures were investigated, which are 60°C for one hour and 37°C 
overnight. In terms of the amount of the immobilized proteins, the TF proteins showed better 
immobilization at 60°C. Interestingly, for the Ni-coated slides, since the immobilization at 
60°C (denaturing condition) was obviously better, that could confirm our suggestion that the 
hidden his-tag is the cause of the improper immobilization and increasing the temperature 
denatures the protein and consequently expose the his-tag to the surface. Nevertheless, from the 
protein functionality side of view, using 60°C as immobilization temperature was working with 
TF proteins but not all when the TF-chip incubated with genomic DNA to check whether the 
proteins are functional or not. Instead, using the combined conditions of 2D-epoxy surface and 
37°C overnight for the protein immobilization kept the TF proteins functional when it was 
incubated with labeled genomic DNA. 
 
4.2.2. Spot morphology 
Spot quality influences the subsequent evaluation of array data and therefore has a 
direct effect on the results reliability. Getting homogeneous uniform spots on the array depends 
Discussion 
93 
on the surface chemistry and the spotting solution [162,164]. In our experiment, we didn’t 
experience a negative effect of the investigated surfaces on the spots morphology. However, 
the spotting solutions showed a great effect on the spots uniformity and homogeneity. For 
instance, in a preliminary experiment, five different conditions for spotting buffer were used 
(PBS, PBS/20% glycerol, 20% glycerol, 0.05% Tween 20 in PBS, PBS/40%, and sodium salt 
rich buffer). As a result, using PBS caused protein drought during the immobilization due to the 
evaporation of the spotting solution and consequently protein aggregation and meanwhile 
protein loss during the washing steps. Adding glycerol either in 20% or 40% v/v increased the 
surface tension of the spots, prevented the evaporation, and subsequently enhanced the spot 
morphology. On the other hand, the presence of high concentration of glycerol in the spotting 
buffer caused a technical problem during the spotting due to sticking of glycerol to the pins and 
subsequently a contamination was experienced. The addition of 0.05% Tween 20 to the 
spotting buffer decreased the surface tension of the spots and therefore increased the spots size. 
Concerning the protein functionality, several solutions were investigated (adding different 
denaturants, adding imidazole, and using the binding buffer) in combination with adding 20% 
glycerol. Adding denaturants was recommended in the previous studies [165]. Therefore, in 
order to solve protein aggregation problem, several denaturants were investigated. Among 
denaturants were urea, SDS, and Tween 20. Interestingly, urea as shown in the result section 
increased the quality of the spots morphology, protein solubility, and even some proteins 
showed better functionality in denaturing solution due to increasing the protein solubility. 
However, again denaturing conditions killed the function of several proteins. Imidazole in the 
spotting buffer resulted in unspecific fluorescent signal during the scanning, which was 
detected in the negative control spots (mere spotting buffer). Therefore, the spotting in the 1X 
binding buffer offered protein solubility (it does have DTT) and the buffer was consistent with 
DNA-protein interaction (the same as hybridization buffer). 
 
4.2.3. Spotted protein concentration 
In order to reach the optimum conditions of interaction array, the proper spotted protein 
concentration was another factor to adjust. In our results, it was shown that the lower the 
concentration the better the signals. Thus, in our experiment, ≤ 100ng of the TF proteins was 
applied to the array surface. Moreover, in a previous study [164], the higher protein 
concentration was not recommended due to the smearing effects in proximity of the spots or 
across the whole slide (comet tail).  
 
Discussion 
94 
4.3. On-chip DNA-protein interaction  
The last step to set up TFs-array was applying DNA-protein interaction on-chip and 
checking reaction specificity. To execute this objective, two steps were followed: 1) 
determination of the reaction specificity via investigating whether the resulted signals on chip 
are produced by DNA-protein interaction or Flourochrome-protein interaction and verifying the 
microarray results with EMSA, and 2) applying TF-response sequences obtained from Transfac 
database or the verified ETS1 and SPI1 Transfac sequence using DNA-array, and applying the 
LGALS4 promoter study with the detected SNPs. 
 
4.3.1. Interaction specificity validation 
In the present study, the determination of the reaction specificity was carried out by two 
means: 1) the general concept of DNA-protein interaction on-chip, and 2) validation of the 
microarray results with EMSA. 
 
The obtained signals from the on-chip DNA-protein interaction were the first concern. 
So, the question was whether the fluorescent signals are the result of the interaction of labeled 
DNA with the TFs protein or just an unspecific interaction between the cyanine3 and cyanine5 
and TF-proteins. Thus, in order to exclude the factor that the resulted fluorescent signals are 
unspecific reaction between the fluorescent dye labels and the transcriptional factors proteins, 
the labeled DNA (PCR product of IL-8) was digested prior to the incubation with TFs-chip. In 
parallel, another TFs-chip was incubated with undigested PCR product of IL-8 promoter. As 
shown in the results, we didn’t obtain any signal in the case of the digested DNA incubation on 
the TFs-array. Therefore, accordingly, the assumption of dye-proteins interaction was excluded.  
 
EMSA [118] was used to validate the microarray results. In a comparison experiment 
between on-chip DNA-protein interaction results and EMSA results, as described earlier in the 
results, a labeled 30-mer double-stranded oligonucleotide from the promoter region of NFKB1 
was incubated with TFs-chip and in parallel separately with each TF-protein in EMSA 
experiment. The obtained results of the two parallel experiments were concordat that indicates 
the specificity of the TF-array results. Interestingly, the microarray results in this experiment 
was much more sensitive. In other words, the resolution of the shifted bands that indicate the 
DNA-protein interaction was too faint (it is difficult to detect). Therefore, microarray results 
were showing advantages over EMSA in being quantitative, sensitive, and specific.  
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4.3.2. Applying oligos and PCR products to TFs-chip 
Another strategy to confirm the specificity of DNA-protein interaction on the array 
surface was applying previously studied sequences. Therefore, the sequences used in this study 
were obtained as the following: 1) retrieved sequences from Transfac database and labeled 
sequences were applied directly on chip, 2) verified Transfac sequences (which underwent 
DNA-microarray study to confirm the binding affinity) in two forms; single binding motif 
sequence and four repeats of the binding sequences according to the previous studies 
[100,149,150], and 3) LGALS4 promoter with the emphasis on the effect of the two SNPs on 
the binding affinity, which is also done by us and explained in details in the first part of this 
thesis. 
 
The obtained short oligos from the Transfac database bound successfully to the target 
proteins. However, on the other hand, the retrieved sequences showed also binding to some 
other proteins and even with stronger signals than the investigated target protein. That could 
indicate unspecific reaction. But, the microarray results were validated using EMSA that was 
completely concordant with the microarray results. Indeed, getting back to the derivation of 
consensus binding motifs for some transcription factors, they were concluded from in vitro 
studies and sequence comparisons of small sets of promoters that are known to bind the 
investigated factor [166]. Subsequently, the identification of the consensus binding sequence of 
the target transcription factor is executed using bioinformatic analyses that search the human 
genome using the consensus motifs or position weight matrices [167,168]. Thus, this approach 
provides all possible locations for a target transcription factor. However, there is many more 
occurrence of a consensus motif for a given factor than there are binding site in the mammalian 
genome [169,170]. Chen et al. found that some regions, called multiple transcription factor-
binding loci (MTLs), were bound by several factors [171]. So, keeping in mind the differences 
between the results of the in vivo and in vitro studies, also the other facts from the previous 
studies (for example, multiple transcription factor loci and the occurrence of consensus 
sequence and the binding sites of the transcription factor in a mammalian genome), could 
strength the suggestion of the inaccuracy of the consensus sequence for a transcription factor. 
In another word, the consensus sequence for a given factor could contain overlapping binding 
sequence(s) for other factors and also the occurrence of this sequence in a promoter region 
doesn’t mean that this promoter will be regulated with that transcription factor. Accordingly, 
we could refer the multiple binding of the Transfac retrieved sequences to several proteins in 
addition to the target protein to this suggestion.  
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In another experiment, the Transfac consensus sequence were validated using DNA 
microarray synthesized using the facility of Geniom and permutation bioinformatic tool to 
investigate the binding affinity of ETS1 and SPI1 under the influence of changing single or 
double nucleotide of their consensus sequence. The highest 50 signals obtained from DNA-
protein interaction were then selected and further analyzed to get the consensus sequence. 
Then, the obtained sequences were applied to TFs protein array. In order to execute DNA-
protein interaction on our protein chip, the obtained consensus sequences were in two forms: 
either single sequence of the motif sequence or four repeats of the binding sequence as used in 
several previous studies [100,149,150]. Using single motif sequence (8-9mers), no signal 
obtained from the DNA-protein interaction on-chip. Weakness and reversibility of the binding 
could interpret the absence of interaction signals, since the binding could be lost during the 
washing steps. In the opposite side, using four repeats of the binding motif sequence resulted in 
not only the binding of the target proteins, but also several other proteins. Actually, that could 
be because the repetition of the polynucleotide sequence could create new binding site(s) for 
other transcription factors. For example, if we have GATC as a consensus sequence. Then we 
will synthesize three repetetion of it GATCGATCGATC. Consequently, for example a 
sequence of CGAT or several other potential possiblities will be created and could be a motif 
for another TF protein. here, an example from in silico analysis of a target sequence is shown in 
figure 30.  
 
Figure 30. An example of the troubleshooting using a sequence which contains 3-4 repeats of 
the binding motifs.  A NFKB1 binding sequence has been retieved from Transfac database 
[172]. Then, the three repeats of the sequence have been analyzed by TESS. As obviously 
shown from the figure, some transcription factor binding sites were created in the interface 
between the successive sequences. 
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Utilizing the promoter study of LGALS4 and the two SNPs effect on its binding in 
combination with TFs-array gave more convincing results regarding the DNA-protein 
interaction specificity on-chip. Since we got concordance between the binding preferences in 
presence or absence of the two SNPs using pull down-mass spectrometry analyses and TFs-
array results. The most obvious result was the case of P53, since in the pull down- mass 
spectrometry analyses showed one hit polypeptide sequence of the protein that bound to the 
wild type but not the mutant. Interestingly, in the microarray results, the interaction of the 
labeled PCR product of LGALS4 promoter with P53 protein on chip showed more than double 
signal intensity with wild type over than mutant type. In addition, concordant results were also 
obtained with RBBP7, ENO1, FUS, and FUBP1 proteins.  
 
Getting the results together, obtaining DNA-protein interaction on-chip was feasible. In 
terms of specificity, several results were obtained: 1) the detected interaction signals were the 
results of DNA-protein interaction and not fluorescent dye-protein interaction, 2) short 
oligonucleotides were confusing, since they bound to the target protein as well as several 
others, and 3) using PCR product of LGALS4 promoter was the most solid results in terms of 
concordance with our LGALS4 promoter study. In conclusion, it is more realistic to use TFs-
array as a DNA-protein assay to study the binding affinity of genes promoters rather than 
discovering the binding motif sequences of transcription factors proteins.  
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